US10758459B2 - Topical formulation of hyperbranched polyglycerol-coated particles thereof - Google Patents
Topical formulation of hyperbranched polyglycerol-coated particles thereof Download PDFInfo
- Publication number
- US10758459B2 US10758459B2 US16/379,224 US201916379224A US10758459B2 US 10758459 B2 US10758459 B2 US 10758459B2 US 201916379224 A US201916379224 A US 201916379224A US 10758459 B2 US10758459 B2 US 10758459B2
- Authority
- US
- United States
- Prior art keywords
- particles
- hpg
- agents
- pla
- nps
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002245 particle Substances 0.000 title claims abstract description 162
- 229920000223 polyglycerol Polymers 0.000 title claims abstract description 19
- 239000012049 topical pharmaceutical composition Substances 0.000 title claims abstract description 6
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 52
- 125000000524 functional group Chemical group 0.000 claims abstract description 35
- 239000000203 mixture Substances 0.000 claims abstract description 32
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 24
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 24
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 22
- 230000000069 prophylactic effect Effects 0.000 claims abstract description 21
- 150000001412 amines Chemical class 0.000 claims abstract description 17
- 235000021436 nutraceutical agent Nutrition 0.000 claims abstract description 14
- 239000002417 nutraceutical Substances 0.000 claims abstract description 13
- 150000002923 oximes Chemical class 0.000 claims abstract description 7
- 150000001299 aldehydes Chemical class 0.000 claims abstract 2
- -1 poly(hydroxy acids) Polymers 0.000 claims description 106
- 238000000034 method Methods 0.000 claims description 60
- 230000008685 targeting Effects 0.000 claims description 36
- 210000001519 tissue Anatomy 0.000 claims description 33
- 239000003814 drug Substances 0.000 claims description 30
- 210000004027 cell Anatomy 0.000 claims description 28
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 17
- 229920001577 copolymer Polymers 0.000 claims description 16
- 238000006243 chemical reaction Methods 0.000 claims description 15
- 238000009472 formulation Methods 0.000 claims description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 14
- 239000000032 diagnostic agent Substances 0.000 claims description 13
- 229940039227 diagnostic agent Drugs 0.000 claims description 13
- 229940124597 therapeutic agent Drugs 0.000 claims description 13
- 229920001600 hydrophobic polymer Polymers 0.000 claims description 10
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 8
- 229920000954 Polyglycolide Polymers 0.000 claims description 8
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 6
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 6
- 210000000056 organ Anatomy 0.000 claims description 5
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 4
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 claims description 4
- XNEFYCZVKIDDMS-UHFFFAOYSA-N avobenzone Chemical compound C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 claims description 4
- 229960005193 avobenzone Drugs 0.000 claims description 4
- 229960001679 octinoxate Drugs 0.000 claims description 4
- FMJSMJQBSVNSBF-UHFFFAOYSA-N octocrylene Chemical group C=1C=CC=CC=1C(=C(C#N)C(=O)OCC(CC)CCCC)C1=CC=CC=C1 FMJSMJQBSVNSBF-UHFFFAOYSA-N 0.000 claims description 4
- 229960000601 octocrylene Drugs 0.000 claims description 4
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 claims description 4
- 229960001173 oxybenzone Drugs 0.000 claims description 4
- 238000011200 topical administration Methods 0.000 claims description 4
- HEOCBCNFKCOKBX-RELGSGGGSA-N (1s,2e,4r)-4,7,7-trimethyl-2-[(4-methylphenyl)methylidene]bicyclo[2.2.1]heptan-3-one Chemical compound C1=CC(C)=CC=C1\C=C/1C(=O)[C@]2(C)CC[C@H]\1C2(C)C HEOCBCNFKCOKBX-RELGSGGGSA-N 0.000 claims description 3
- MEZZCSHVIGVWFI-UHFFFAOYSA-N 2,2'-Dihydroxy-4-methoxybenzophenone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1O MEZZCSHVIGVWFI-UHFFFAOYSA-N 0.000 claims description 3
- JGUMTYWKIBJSTN-UHFFFAOYSA-N 2-ethylhexyl 4-[[4,6-bis[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 JGUMTYWKIBJSTN-UHFFFAOYSA-N 0.000 claims description 3
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 claims description 3
- WSSJONWNBBTCMG-UHFFFAOYSA-N 2-hydroxybenzoic acid (3,3,5-trimethylcyclohexyl) ester Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C1=CC=CC=C1O WSSJONWNBBTCMG-UHFFFAOYSA-N 0.000 claims description 3
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 claims description 3
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 3
- FMRHJJZUHUTGKE-UHFFFAOYSA-N Ethylhexyl salicylate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1O FMRHJJZUHUTGKE-UHFFFAOYSA-N 0.000 claims description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 3
- HEAHZSUCFKFERC-LRVMPXQBSA-N [(2e)-2-[[4-[(z)-[7,7-dimethyl-3-oxo-4-(sulfomethyl)-2-bicyclo[2.2.1]heptanylidene]methyl]phenyl]methylidene]-7,7-dimethyl-3-oxo-4-bicyclo[2.2.1]heptanyl]methanesulfonic acid Chemical compound CC1(C)C2CCC1(CS(O)(=O)=O)C(=O)\C2=C/C(C=C1)=CC=C1\C=C/1C(=O)C2(CS(O)(=O)=O)CCC\1C2(C)C HEAHZSUCFKFERC-LRVMPXQBSA-N 0.000 claims description 3
- UBNYRXMKIIGMKK-RMKNXTFCSA-N amiloxate Chemical compound COC1=CC=C(\C=C\C(=O)OCCC(C)C)C=C1 UBNYRXMKIIGMKK-RMKNXTFCSA-N 0.000 claims description 3
- 229960002709 amiloxate Drugs 0.000 claims description 3
- 229960004050 aminobenzoic acid Drugs 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 3
- XVAMCHGMPYWHNL-UHFFFAOYSA-N bemotrizinol Chemical compound OC1=CC(OCC(CC)CCCC)=CC=C1C1=NC(C=2C=CC(OC)=CC=2)=NC(C=2C(=CC(OCC(CC)CCCC)=CC=2)O)=N1 XVAMCHGMPYWHNL-UHFFFAOYSA-N 0.000 claims description 3
- 229960004101 bemotrizinol Drugs 0.000 claims description 3
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 3
- 229940127093 camptothecin Drugs 0.000 claims description 3
- CMDKPGRTAQVGFQ-RMKNXTFCSA-N cinoxate Chemical compound CCOCCOC(=O)\C=C\C1=CC=C(OC)C=C1 CMDKPGRTAQVGFQ-RMKNXTFCSA-N 0.000 claims description 3
- 229960001063 cinoxate Drugs 0.000 claims description 3
- FDATWRLUYRHCJE-UHFFFAOYSA-N diethylamino hydroxybenzoyl hexyl benzoate Chemical compound CCCCCCOC(=O)C1=CC=CC=C1C(=O)C1=CC=C(N(CC)CC)C=C1O FDATWRLUYRHCJE-UHFFFAOYSA-N 0.000 claims description 3
- 229960004960 dioxybenzone Drugs 0.000 claims description 3
- GLCJMPWWQKKJQZ-UHFFFAOYSA-L disodium;2-[4-(4,6-disulfonato-1h-benzimidazol-2-yl)phenyl]-1h-benzimidazole-4,6-disulfonate;hydron Chemical compound [Na+].[Na+].C1=C(S(O)(=O)=O)C=C2NC(C3=CC=C(C=C3)C3=NC4=C(C=C(C=C4N3)S(=O)(=O)O)S([O-])(=O)=O)=NC2=C1S([O-])(=O)=O GLCJMPWWQKKJQZ-UHFFFAOYSA-L 0.000 claims description 3
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 3
- HUVYTMDMDZRHBN-UHFFFAOYSA-N drometrizole trisiloxane Chemical compound C[Si](C)(C)O[Si](C)(O[Si](C)(C)C)CC(C)CC1=CC(C)=CC(N2N=C3C=CC=CC3=N2)=C1O HUVYTMDMDZRHBN-UHFFFAOYSA-N 0.000 claims description 3
- 229960003747 ecamsule Drugs 0.000 claims description 3
- UVCJGUGAGLDPAA-UHFFFAOYSA-N ensulizole Chemical compound N1C2=CC(S(=O)(=O)O)=CC=C2N=C1C1=CC=CC=C1 UVCJGUGAGLDPAA-UHFFFAOYSA-N 0.000 claims description 3
- 229960000655 ensulizole Drugs 0.000 claims description 3
- 229960004697 enzacamene Drugs 0.000 claims description 3
- 210000002744 extracellular matrix Anatomy 0.000 claims description 3
- 229960004881 homosalate Drugs 0.000 claims description 3
- SOXAGEOHPCXXIO-DVOMOZLQSA-N menthyl anthranilate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)C1=CC=CC=C1N SOXAGEOHPCXXIO-DVOMOZLQSA-N 0.000 claims description 3
- 229960002248 meradimate Drugs 0.000 claims description 3
- 229960003921 octisalate Drugs 0.000 claims description 3
- 239000005014 poly(hydroxyalkanoate) Substances 0.000 claims description 3
- 229920000903 polyhydroxyalkanoate Polymers 0.000 claims description 3
- 229920002282 polysilicones-15 Polymers 0.000 claims description 3
- CXVGEDCSTKKODG-UHFFFAOYSA-N sulisobenzone Chemical compound C1=C(S(O)(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 CXVGEDCSTKKODG-UHFFFAOYSA-N 0.000 claims description 3
- 229960000368 sulisobenzone Drugs 0.000 claims description 3
- UEVAMYPIMMOEFW-UHFFFAOYSA-N trolamine salicylate Chemical compound OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O UEVAMYPIMMOEFW-UHFFFAOYSA-N 0.000 claims description 3
- 229940030300 trolamine salicylate Drugs 0.000 claims description 3
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 2
- 108010036949 Cyclosporine Proteins 0.000 claims description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 229920002732 Polyanhydride Polymers 0.000 claims description 2
- 229920001710 Polyorthoester Polymers 0.000 claims description 2
- 229940009456 adriamycin Drugs 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 230000002141 anti-parasite Effects 0.000 claims description 2
- 239000003443 antiviral agent Substances 0.000 claims description 2
- 229940121357 antivirals Drugs 0.000 claims description 2
- 229960004562 carboplatin Drugs 0.000 claims description 2
- 229960001265 ciclosporin Drugs 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- 210000004087 cornea Anatomy 0.000 claims description 2
- 229930182912 cyclosporin Natural products 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 229930013356 epothilone Natural products 0.000 claims description 2
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- 229960004857 mitomycin Drugs 0.000 claims description 2
- 210000004877 mucosa Anatomy 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 229950000516 padimate Drugs 0.000 claims 1
- LXTZRIBXKVRLOA-UHFFFAOYSA-N padimate a Chemical compound CCCCCOC(=O)C1=CC=C(N(C)C)C=C1 LXTZRIBXKVRLOA-UHFFFAOYSA-N 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 abstract description 229
- 239000000463 material Substances 0.000 abstract description 47
- 238000000576 coating method Methods 0.000 abstract description 19
- 230000002209 hydrophobic effect Effects 0.000 abstract description 15
- 239000011248 coating agent Substances 0.000 abstract description 13
- 238000010521 absorption reaction Methods 0.000 abstract description 10
- 230000001225 therapeutic effect Effects 0.000 abstract description 6
- 239000011258 core-shell material Substances 0.000 abstract description 3
- WYWZRNAHINYAEF-AWEZNQCLSA-N [(2s)-2-ethylhexyl] 4-(dimethylamino)benzoate Chemical compound CCCC[C@H](CC)COC(=O)C1=CC=C(N(C)C)C=C1 WYWZRNAHINYAEF-AWEZNQCLSA-N 0.000 description 94
- 229960002638 padimate o Drugs 0.000 description 93
- 210000003491 skin Anatomy 0.000 description 77
- 229920000642 polymer Polymers 0.000 description 68
- 230000000475 sunscreen effect Effects 0.000 description 46
- 239000000516 sunscreening agent Substances 0.000 description 46
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 42
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 32
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- 239000002953 phosphate buffered saline Substances 0.000 description 30
- 208000027418 Wounds and injury Diseases 0.000 description 26
- 206010052428 Wound Diseases 0.000 description 25
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- 229920001223 polyethylene glycol Polymers 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 239000004904 UV filter Substances 0.000 description 21
- 235000018102 proteins Nutrition 0.000 description 21
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 20
- 239000000227 bioadhesive Substances 0.000 description 19
- 239000000839 emulsion Substances 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 16
- 238000010168 coupling process Methods 0.000 description 16
- 229920002451 polyvinyl alcohol Polymers 0.000 description 16
- 239000003446 ligand Substances 0.000 description 15
- 239000011162 core material Substances 0.000 description 14
- 238000005859 coupling reaction Methods 0.000 description 14
- 239000000975 dye Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 239000004372 Polyvinyl alcohol Substances 0.000 description 13
- 239000013543 active substance Substances 0.000 description 13
- 230000008878 coupling Effects 0.000 description 13
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 13
- 239000002202 Polyethylene glycol Substances 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 239000011859 microparticle Substances 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 238000011534 incubation Methods 0.000 description 11
- 238000002296 dynamic light scattering Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 230000014759 maintenance of location Effects 0.000 description 10
- 230000000699 topical effect Effects 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 150000002009 diols Chemical group 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 125000005647 linker group Chemical group 0.000 description 9
- 239000002480 mineral oil Substances 0.000 description 9
- 235000010446 mineral oil Nutrition 0.000 description 9
- 230000035515 penetration Effects 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 8
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- 229920004890 Triton X-100 Polymers 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 210000003780 hair follicle Anatomy 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 238000004627 transmission electron microscopy Methods 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 206010042496 Sunburn Diseases 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 239000011521 glass Substances 0.000 description 7
- 239000003999 initiator Substances 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- 210000000434 stratum corneum Anatomy 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 239000013504 Triton X-100 Substances 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 229940098773 bovine serum albumin Drugs 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 229920002678 cellulose Polymers 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 238000005538 encapsulation Methods 0.000 description 6
- 210000002615 epidermis Anatomy 0.000 description 6
- 238000003384 imaging method Methods 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000003381 stabilizer Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 5
- 108091023037 Aptamer Proteins 0.000 description 5
- 229940021995 DNA vaccine Drugs 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 108010039918 Polylysine Proteins 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 235000010980 cellulose Nutrition 0.000 description 5
- 239000000562 conjugate Substances 0.000 description 5
- 210000004207 dermis Anatomy 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 5
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 5
- 229960004194 lidocaine Drugs 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 238000011580 nude mouse model Methods 0.000 description 5
- 229920000656 polylysine Polymers 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 238000001179 sorption measurement Methods 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 210000004243 sweat Anatomy 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- CTKINSOISVBQLD-UHFFFAOYSA-N Glycidol Chemical compound OCC1CO1 CTKINSOISVBQLD-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 125000003172 aldehyde group Chemical group 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 239000012620 biological material Substances 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 4
- 125000002091 cationic group Chemical group 0.000 description 4
- 230000021615 conjugation Effects 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000003176 fibrotic effect Effects 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 150000002429 hydrazines Chemical class 0.000 description 4
- 229920001477 hydrophilic polymer Polymers 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000004005 microsphere Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 150000002894 organic compounds Chemical class 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- 238000000935 solvent evaporation Methods 0.000 description 4
- 238000000527 sonication Methods 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 201000004384 Alopecia Diseases 0.000 description 3
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 3
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 108010076876 Keratins Proteins 0.000 description 3
- 102000011782 Keratins Human genes 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 239000004952 Polyamide Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000035587 bioadhesion Effects 0.000 description 3
- 229920002988 biodegradable polymer Polymers 0.000 description 3
- 239000004621 biodegradable polymer Substances 0.000 description 3
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 3
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000007822 coupling agent Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000005227 gel permeation chromatography Methods 0.000 description 3
- 210000004209 hair Anatomy 0.000 description 3
- 208000024963 hair loss Diseases 0.000 description 3
- 230000003676 hair loss Effects 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000003278 mimic effect Effects 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 230000037311 normal skin Effects 0.000 description 3
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000005191 phase separation Methods 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 229920002647 polyamide Polymers 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 150000003077 polyols Chemical class 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 3
- 239000012798 spherical particle Substances 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 238000003260 vortexing Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- YHTTWXCDIRTOQX-FQJIPJFPSA-N (6S,9S,15S,18R,23R,26S,29S)-18-amino-6-(4-aminobutyl)-9,26-bis(carboxymethyl)-15-[3-(diaminomethylideneamino)propyl]-2,5,8,11,14,17,25,28-octaoxo-20,21-dithia-1,4,7,10,13,16,24,27-octazabicyclo[27.3.0]dotriacontane-23-carboxylic acid Chemical compound NCCCC[C@@H]1NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]2CCCN2C(=O)CNC1=O)C(O)=O YHTTWXCDIRTOQX-FQJIPJFPSA-N 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 2
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- SZJXEIBPJWMWQR-UHFFFAOYSA-N 2-methylpropane-1,1,1-triol Chemical group CC(C)C(O)(O)O SZJXEIBPJWMWQR-UHFFFAOYSA-N 0.000 description 2
- RJWBTWIBUIGANW-UHFFFAOYSA-M 4-chlorobenzenesulfonate Chemical class [O-]S(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-M 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- QTGIAADRBBLJGA-UHFFFAOYSA-N Articaine Chemical compound CCCNC(C)C(=O)NC=1C(C)=CSC=1C(=O)OC QTGIAADRBBLJGA-UHFFFAOYSA-N 0.000 description 2
- 101100298998 Caenorhabditis elegans pbs-3 gene Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 108010041986 DNA Vaccines Proteins 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 238000011771 FVB mouse Methods 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 102100034533 Histone H2AX Human genes 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 230000006750 UV protection Effects 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 241000021375 Xenogenes Species 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 229920003232 aliphatic polyester Polymers 0.000 description 2
- 238000010539 anionic addition polymerization reaction Methods 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 239000012062 aqueous buffer Substances 0.000 description 2
- 150000004982 aromatic amines Chemical class 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000012867 bioactive agent Substances 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 229960003150 bupivacaine Drugs 0.000 description 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 238000000237 capillary viscometry Methods 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 125000002843 carboxylic acid group Chemical group 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 229960001747 cinchocaine Drugs 0.000 description 2
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- OWQIUQKMMPDHQQ-UHFFFAOYSA-N dimethocaine Chemical compound CCN(CC)CC(C)(C)COC(=O)C1=CC=C(N)C=C1 OWQIUQKMMPDHQQ-UHFFFAOYSA-N 0.000 description 2
- 229950010160 dimethocaine Drugs 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 2
- GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 238000004299 exfoliation Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 229960005540 iRGD Drugs 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 229910010272 inorganic material Inorganic materials 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000010859 live-cell imaging Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000001690 micro-dialysis Methods 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- 229920002113 octoxynol Polymers 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 150000002924 oxiranes Chemical class 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920001308 poly(aminoacid) Polymers 0.000 description 2
- 229920001281 polyalkylene Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- BDAWXSQJJCIFIK-UHFFFAOYSA-N potassium methoxide Chemical compound [K+].[O-]C BDAWXSQJJCIFIK-UHFFFAOYSA-N 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- 239000000473 propyl gallate Substances 0.000 description 2
- 235000010388 propyl gallate Nutrition 0.000 description 2
- 229940075579 propyl gallate Drugs 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- 229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- RPENMORRBUTCPR-UHFFFAOYSA-M sodium;1-hydroxy-2,5-dioxopyrrolidine-3-sulfonate Chemical group [Na+].ON1C(=O)CC(S([O-])(=O)=O)C1=O RPENMORRBUTCPR-UHFFFAOYSA-M 0.000 description 2
- WQQPDTLGLVLNOH-UHFFFAOYSA-M sodium;4-hydroxy-4-oxo-3-sulfobutanoate Chemical class [Na+].OC(=O)CC(C([O-])=O)S(O)(=O)=O WQQPDTLGLVLNOH-UHFFFAOYSA-M 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960002372 tetracaine Drugs 0.000 description 2
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- IRPKBYJYVJOQHQ-UHFFFAOYSA-M (2e)-2-[(2e)-2-[2-chloro-3-[(e)-2-(3,3-dimethyl-1-propylindol-1-ium-2-yl)ethenyl]cyclohex-2-en-1-ylidene]ethylidene]-3,3-dimethyl-1-propylindole;iodide Chemical compound [I-].CC1(C)C2=CC=CC=C2N(CCC)\C1=C\C=C/1C(Cl)=C(\C=C/C=2C(C3=CC=CC=C3[N+]=2CCC)(C)C)CCC\1 IRPKBYJYVJOQHQ-UHFFFAOYSA-M 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- VQKDJSXHVSAIAR-UHFFFAOYSA-N 1h-imidazol-2-yl carbamate Chemical compound NC(=O)OC1=NC=CN1 VQKDJSXHVSAIAR-UHFFFAOYSA-N 0.000 description 1
- WSNDAYQNZRJGMJ-UHFFFAOYSA-N 2,2,2-trifluoroethanone Chemical compound FC(F)(F)[C]=O WSNDAYQNZRJGMJ-UHFFFAOYSA-N 0.000 description 1
- RPZANUYHRMRTTE-UHFFFAOYSA-N 2,3,4-trimethoxy-6-(methoxymethyl)-5-[3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxyoxane;1-[[3,4,5-tris(2-hydroxybutoxy)-6-[4,5,6-tris(2-hydroxybutoxy)-2-(2-hydroxybutoxymethyl)oxan-3-yl]oxyoxan-2-yl]methoxy]butan-2-ol Chemical compound COC1C(OC)C(OC)C(COC)OC1OC1C(OC)C(OC)C(OC)OC1COC.CCC(O)COC1C(OCC(O)CC)C(OCC(O)CC)C(COCC(O)CC)OC1OC1C(OCC(O)CC)C(OCC(O)CC)C(OCC(O)CC)OC1COCC(O)CC RPZANUYHRMRTTE-UHFFFAOYSA-N 0.000 description 1
- 125000001917 2,4-dinitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1*)[N+]([O-])=O)[N+]([O-])=O 0.000 description 1
- GVJXGCIPWAVXJP-UHFFFAOYSA-N 2,5-dioxo-1-oxoniopyrrolidine-3-sulfonate Chemical compound ON1C(=O)CC(S(O)(=O)=O)C1=O GVJXGCIPWAVXJP-UHFFFAOYSA-N 0.000 description 1
- 150000003923 2,5-pyrrolediones Chemical group 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- LWNPNOFGINFGGV-UHFFFAOYSA-N 2-(diethylamino)-n-(2,6-dimethylphenyl)acetamide;2-(dimethylamino)ethyl 4-(butylamino)benzoate Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C.CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 LWNPNOFGINFGGV-UHFFFAOYSA-N 0.000 description 1
- WZSPWMATVLBWRS-UHFFFAOYSA-N 2-(diethylamino)-n-(2,6-dimethylphenyl)acetamide;n-(2-methylphenyl)-2-(propylamino)propanamide Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C.CCN(CC)CC(=O)NC1=C(C)C=CC=C1C WZSPWMATVLBWRS-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- POAOYUHQDCAZBD-UHFFFAOYSA-N 2-butoxyethanol Chemical compound CCCCOCCO POAOYUHQDCAZBD-UHFFFAOYSA-N 0.000 description 1
- CTXGTHVAWRBISV-UHFFFAOYSA-N 2-hydroxyethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCO CTXGTHVAWRBISV-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- VCNPGCHIKPSUSP-UHFFFAOYSA-N 2-hydroxypropyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(C)O VCNPGCHIKPSUSP-UHFFFAOYSA-N 0.000 description 1
- AEDQNOLIADXSBB-UHFFFAOYSA-N 3-(dodecylazaniumyl)propanoate Chemical compound CCCCCCCCCCCCNCCC(O)=O AEDQNOLIADXSBB-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010000349 Acanthosis Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- AQVATIWRBNWJJT-UHFFFAOYSA-N C1CCOCC1.CCC(COCC(O)COCC(O)CO)(COCC(O)COCC(CO)OCC(O)CO)COCC(COCC(COCC(O)COCC(O)CO)OCC(COCC(O)CO)OCC(O)CO)OCC(CO)OCC(CO)OCC(O)CO.CCCC(CO)(CO)CO.CO[K].OCC1CC1.[H]OC(C)C(=O)OC(C)C(=O)O.[H]OC(C)C(=O)OC(C)C(=O)OC(COCC(CO)OCC(O)CO)COCC(CC)(COCC(O)COCC(O)CO)COCC(COCC(COCC(O)COCC(O)CO)OCC(COCC(O)CO)OCC(O)CO)OCC(CO)OCC(CO)OCC(O)CO Chemical compound C1CCOCC1.CCC(COCC(O)COCC(O)CO)(COCC(O)COCC(CO)OCC(O)CO)COCC(COCC(COCC(O)COCC(O)CO)OCC(COCC(O)CO)OCC(O)CO)OCC(CO)OCC(CO)OCC(O)CO.CCCC(CO)(CO)CO.CO[K].OCC1CC1.[H]OC(C)C(=O)OC(C)C(=O)O.[H]OC(C)C(=O)OC(C)C(=O)OC(COCC(CO)OCC(O)CO)COCC(CC)(COCC(O)COCC(O)CO)COCC(COCC(COCC(O)COCC(O)CO)OCC(COCC(O)CO)OCC(O)CO)OCC(CO)OCC(CO)OCC(O)CO AQVATIWRBNWJJT-UHFFFAOYSA-N 0.000 description 1
- 208000019300 CLIPPERS Diseases 0.000 description 1
- NZRYKGHSUAUMAO-UHFFFAOYSA-N COCC(CC(C)(C)C)OC Chemical compound COCC(CC(C)(C)C)OC NZRYKGHSUAUMAO-UHFFFAOYSA-N 0.000 description 1
- RIORDBWYNRSEQC-UHFFFAOYSA-N COCC(COC(C)(C)C)OC Chemical compound COCC(COC(C)(C)C)OC RIORDBWYNRSEQC-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- DQEFEBPAPFSJLV-UHFFFAOYSA-N Cellulose propionate Chemical compound CCC(=O)OCC1OC(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C1OC1C(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C(COC(=O)CC)O1 DQEFEBPAPFSJLV-UHFFFAOYSA-N 0.000 description 1
- 229920002284 Cellulose triacetate Polymers 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 241001340526 Chrysoclista linneella Species 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 102000017286 Histone H2A Human genes 0.000 description 1
- 108050005231 Histone H2A Proteins 0.000 description 1
- 101710195517 Histone H2AX Proteins 0.000 description 1
- 101001067891 Homo sapiens Histone H2AX Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 238000012695 Interfacial polymerization Methods 0.000 description 1
- 206010066295 Keratosis pilaris Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010031099 Mannose Receptor Proteins 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 102000001621 Mucoproteins Human genes 0.000 description 1
- 108010093825 Mucoproteins Proteins 0.000 description 1
- PPEKGEBBBBNZKS-UHFFFAOYSA-N Neosaxitoxin Natural products N=C1N(O)C(COC(=O)N)C2N=C(N)NC22C(O)(O)CCN21 PPEKGEBBBBNZKS-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- YQKAVWCGQQXBGW-UHFFFAOYSA-N Piperocaine Chemical compound CC1CCCCN1CCCOC(=O)C1=CC=CC=C1 YQKAVWCGQQXBGW-UHFFFAOYSA-N 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920006022 Poly(L-lactide-co-glycolide)-b-poly(ethylene glycol) Polymers 0.000 description 1
- 229920001305 Poly(isodecyl(meth)acrylate) Polymers 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 229920002319 Poly(methyl acrylate) Polymers 0.000 description 1
- 229920000805 Polyaspartic acid Polymers 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 229920001273 Polyhydroxy acid Polymers 0.000 description 1
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 description 1
- CAJIGINSTLKQMM-UHFFFAOYSA-N Propoxycaine Chemical compound CCCOC1=CC(N)=CC=C1C(=O)OCCN(CC)CC CAJIGINSTLKQMM-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 1
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000005262 alkoxyamine group Chemical group 0.000 description 1
- 150000008055 alkyl aryl sulfonates Chemical class 0.000 description 1
- 229920013820 alkyl cellulose Polymers 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 description 1
- SOIFLUNRINLCBN-UHFFFAOYSA-N ammonium thiocyanate Chemical compound [NH4+].[S-]C#N SOIFLUNRINLCBN-UHFFFAOYSA-N 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000000058 anti acne agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940124340 antiacne agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 229960003831 articaine Drugs 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229960001716 benzalkonium Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- JZUVESQYEHERMD-UHFFFAOYSA-N bis[(4-nitrophenyl)methyl] carbonate Chemical compound C1=CC([N+](=O)[O-])=CC=C1COC(=O)OCC1=CC=C([N+]([O-])=O)C=C1 JZUVESQYEHERMD-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 229920006218 cellulose propionate Polymers 0.000 description 1
- 229960000800 cetrimonium bromide Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- UPUOLJWYFICKJI-UHFFFAOYSA-N cyclobutane;pyrimidine Chemical class C1CCC1.C1=CN=CN=C1 UPUOLJWYFICKJI-UHFFFAOYSA-N 0.000 description 1
- 229960004741 cyclomethycaine Drugs 0.000 description 1
- YLRNESBGEGGQBK-UHFFFAOYSA-N cyclomethycaine Chemical compound CC1CCCCN1CCCOC(=O)C(C=C1)=CC=C1OC1CCCCC1 YLRNESBGEGGQBK-UHFFFAOYSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 150000004845 diazirines Chemical group 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- FDPIMTJIUBPUKL-UHFFFAOYSA-N dimethylacetone Natural products CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000003618 dip coating Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 231100000507 endocrine disrupting Toxicity 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 210000003426 epidermal langerhans cell Anatomy 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- MWFJXRUUPWIALU-UHFFFAOYSA-N ethyl ethenesulfonate Chemical compound CCOS(=O)(=O)C=C MWFJXRUUPWIALU-UHFFFAOYSA-N 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 229960003976 etidocaine Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 210000004186 follicle cell Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 125000005179 haloacetyl group Chemical group 0.000 description 1
- 239000002920 hazardous waste Substances 0.000 description 1
- 244000000013 helminth Species 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 239000012943 hotmelt Substances 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 239000010954 inorganic particle Substances 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 208000001875 irritant dermatitis Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000012948 isocyanate Chemical group 0.000 description 1
- 150000002513 isocyanates Chemical group 0.000 description 1
- 150000002540 isothiocyanates Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 229940094506 lauryl betaine Drugs 0.000 description 1
- IZWSFJTYBVKZNK-UHFFFAOYSA-N lauryl sulfobetaine Chemical compound CCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O IZWSFJTYBVKZNK-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960004288 levobupivacaine Drugs 0.000 description 1
- LEBVLXFERQHONN-INIZCTEOSA-N levobupivacaine Chemical compound CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-INIZCTEOSA-N 0.000 description 1
- 229940119319 lidocaine / prilocaine Drugs 0.000 description 1
- 229940000243 lidocaine / tetracaine Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229920001427 mPEG Polymers 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 239000000696 magnetic material Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229960002409 mepivacaine Drugs 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 239000013528 metallic particle Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- QCTVGFNUKWXQNN-UHFFFAOYSA-N n-(2-hydroxypropyl)octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCC(C)O QCTVGFNUKWXQNN-UHFFFAOYSA-N 0.000 description 1
- DVEKCXOJTLDBFE-UHFFFAOYSA-N n-dodecyl-n,n-dimethylglycinate Chemical compound CCCCCCCCCCCC[N+](C)(C)CC([O-])=O DVEKCXOJTLDBFE-UHFFFAOYSA-N 0.000 description 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- PPEKGEBBBBNZKS-HGRQIUPRSA-N neosaxitoxin Chemical compound N=C1N(O)[C@@H](COC(=O)N)[C@@H]2NC(=N)N[C@@]22C(O)(O)CCN21 PPEKGEBBBBNZKS-HGRQIUPRSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940053973 novocaine Drugs 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229920002114 octoxynol-9 Polymers 0.000 description 1
- 150000002905 orthoesters Chemical class 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000002186 photoactivation Effects 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 230000000886 photobiology Effects 0.000 description 1
- 238000001782 photodegradation Methods 0.000 description 1
- 208000007578 phototoxic dermatitis Diseases 0.000 description 1
- 231100000018 phototoxicity Toxicity 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 229960001045 piperocaine Drugs 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 1
- 229920001490 poly(butyl methacrylate) polymer Polymers 0.000 description 1
- 229920000111 poly(butyric acid) Polymers 0.000 description 1
- 229920001483 poly(ethyl methacrylate) polymer Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 1
- 229920000212 poly(isobutyl acrylate) Polymers 0.000 description 1
- 229920000205 poly(isobutyl methacrylate) Polymers 0.000 description 1
- 229940065514 poly(lactide) Drugs 0.000 description 1
- 229920001306 poly(lactide-co-caprolactone) Polymers 0.000 description 1
- 229920000196 poly(lauryl methacrylate) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000184 poly(octadecyl acrylate) Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 108010064470 polyaspartate Proteins 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 229940056099 polyglyceryl-4 oleate Drugs 0.000 description 1
- 229920000129 polyhexylmethacrylate Polymers 0.000 description 1
- 229920000197 polyisopropyl acrylate Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000000580 polymer-drug conjugate Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920000182 polyphenyl methacrylate Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920001290 polyvinyl ester Polymers 0.000 description 1
- 229920001289 polyvinyl ether Polymers 0.000 description 1
- 229920001291 polyvinyl halide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- RWPGFSMJFRPDDP-UHFFFAOYSA-L potassium metabisulfite Chemical compound [K+].[K+].[O-]S(=O)S([O-])(=O)=O RWPGFSMJFRPDDP-UHFFFAOYSA-L 0.000 description 1
- 229940043349 potassium metabisulfite Drugs 0.000 description 1
- 235000010263 potassium metabisulphite Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960001807 prilocaine Drugs 0.000 description 1
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 description 1
- 229960005094 prilocaine hydrochloride Drugs 0.000 description 1
- BJPJNTKRKALCPP-UHFFFAOYSA-N prilocaine hydrochloride Chemical compound [Cl-].CCC[NH2+]C(C)C(=O)NC1=CC=CC=C1C BJPJNTKRKALCPP-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- LBUSGXDHOHEPQQ-UHFFFAOYSA-N propane-1,1,1-triol Chemical compound CCC(O)(O)O LBUSGXDHOHEPQQ-UHFFFAOYSA-N 0.000 description 1
- 229960003981 proparacaine Drugs 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229940095574 propionic acid Drugs 0.000 description 1
- 229950003255 propoxycaine Drugs 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001846 repelling effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 229960001549 ropivacaine Drugs 0.000 description 1
- RPQXVSUAYFXFJA-HGRQIUPRSA-N saxitoxin Chemical compound NC(=O)OC[C@@H]1N=C(N)N2CCC(O)(O)[C@@]22N=C(N)N[C@@H]12 RPQXVSUAYFXFJA-HGRQIUPRSA-N 0.000 description 1
- RPQXVSUAYFXFJA-UHFFFAOYSA-N saxitoxin hydrate Natural products NC(=O)OCC1N=C(N)N2CCC(O)(O)C22NC(N)=NC12 RPQXVSUAYFXFJA-UHFFFAOYSA-N 0.000 description 1
- 238000004621 scanning probe microscopy Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 102000014452 scavenger receptors Human genes 0.000 description 1
- 108010078070 scavenger receptors Proteins 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 229940003547 septocaine Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 229940001607 sodium bisulfite Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 1
- 229960002218 sodium chlorite Drugs 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 239000004296 sodium metabisulphite Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- IDXHDUOOTUFFOX-UHFFFAOYSA-M sodium;2-[2-hydroxyethyl-[2-(tetradecanoylamino)ethyl]amino]acetate Chemical compound [Na+].CCCCCCCCCCCCCC(=O)NCCN(CCO)CC([O-])=O IDXHDUOOTUFFOX-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229940100515 sorbitan Drugs 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 239000012209 synthetic fiber Substances 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 229920001897 terpolymer Polymers 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 description 1
- 229950010357 tetrodotoxin Drugs 0.000 description 1
- CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000008009 topical excipient Substances 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- GOZBHBFUQHMKQB-UHFFFAOYSA-N trimecaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=C(C)C=C1C GOZBHBFUQHMKQB-UHFFFAOYSA-N 0.000 description 1
- 229950002569 trimecaine Drugs 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000004072 triols Chemical class 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
- 239000011667 zinc carbonate Substances 0.000 description 1
- 235000004416 zinc carbonate Nutrition 0.000 description 1
- 229910000010 zinc carbonate Inorganic materials 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0241—Containing particulates characterized by their shape and/or structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
- A61K47/6937—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/90—Block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
- C07C59/06—Glycolic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
- C07C59/08—Lactic acid
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
- C08G83/002—Dendritic macromolecules
- C08G83/005—Hyperbranched macromolecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/413—Nanosized, i.e. having sizes below 100 nm
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/60—Particulates further characterized by their structure or composition
- A61K2800/61—Surface treated
- A61K2800/62—Coated
- A61K2800/624—Coated by macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- This invention is in the field of particles, such as microparticles and/or nanoparticles, coated with hyperbranched polyglycerol, wherein the coating can be tuned to provide stealth or adhesive properties.
- UV radiation from sunlight can lead to multiple adverse effects including cutaneous phototoxicity (sunburn), photoaging, and carcinogenesis (Federman et al., JAMA 312:87-88 (2014); Stern et al, Journal of the American Academy of Dermatology 44:755-761 (2001)).
- UVB directly induces cyclopyrimidine dimers (CPDs) within the genomic DNA (gDNA) of keratinocytes, and both UVA and UVB exposure markedly enhance production of reactive oxidation species (ROS) that damage a variety of cellular components, including gDNA (Gilchrest, B. A.
- UV-exposure is clearly linked to both melanoma and non-melanoma skin cancer development (Gordon et al, Facial Plastic Surgery: FPS 29:402-410 (2013)).
- organic UV filters e.g. avobenzone, octinoxate, octocrylene, oxybenzone and padimate O (PO) (Hayden et al., Skin Pharmacol. Physiol.
- UV-blocking inorganic materials such as micronized zinc oxide (ZnO) and titanium dioxide (TiO 2 ) particles (Barnard, Nature Nanotechnology, 5:271-274 (2010)) have been utilized. While transdermal penetration of the inorganic particles appears to be less of a concern than for the organic agents, both types of sunblock agents have shown the capacity to enhance ROS generation after UV exposure, suggesting even small quantities may contribute to cellular damage and ultimately carcinogenesis (Pan et al., Small, 5:511-520 (2009); Trouiller et al., Cancer Res.
- ZnO micronized zinc oxide
- TiO 2 titanium dioxide
- UV filters Biohazard: Treat As Hazardous Waste. (New Voice Publications (2011)).
- UV filters have been detected in human urine and breast milk samples after tropical treatment, and may mediate systemic effects including endocrine disruption (Hayden et al., Skin Pharmacol. Physiol. 18:170-174 (2005); Krause et al., Int. J. Androl. 35:424-436 (2012); Hayden et al., Lancet, 350:863-864 (1997)). Therefore, preventing direct skin contact and subsequent epidermal penetration may be essential to eliminating the potential adverse effects of sunscreens.
- sunscreens polymerize monomers with an initiator in order to stabilize the UV filters into a film that coats the skin.
- the chemicals involved include a variety of acrylate derivatives and multiple initiators (Nair et al., Pigment Cell and Melanoma Research 27:843-845 (2014), which have been implicated in irritant and allergic contact dermatitis (Bennassar et al., Dermatology Online Journal 15:14 (2009); Rietschel, R. L. Fisher's Contact Dermatitis. (Pmph Usa; 6 edition (Apr. 2, 2007)).
- Core-shell particles such as microparticles and nanoparticles, and methods of making and using thereof are described herein.
- the core is formed of or contains a hydrophobic material, preferably polymeric.
- the shell is formed of or contains hyperbranched polyglycerol (HPG).
- HPG hyperbranched polyglycerol
- the HPG can be covalently bound to the one or more materials that form the core such that the hydrophilic HPG is oriented towards the outside of the particles and the hydrophobic material oriented to form the core.
- the HPG coating can be modified to adjust the properties of the particles.
- unmodified HPG coatings impart stealth properties to the particles which resist non-specific protein absorption.
- the hydroxyl groups on the HPG coating can be chemically modified to form functional groups that react with functional groups on tissue or otherwise interact with tissue to adhere the particles to the tissue, cells, or extracellular materials, such as proteins.
- Such functional groups include, but not limited to, aldehydes, amines, and O-substituted oximes.
- Topical formulations for application to the skin contain these HPG coated nanoparticles.
- Nanoparticles with unusually strong bioadhesive properties do not diffuse into hair follicles and are useful as sunscreens or delivery of therapeutic, prophylactic, diagnostic or nutraceutical agents.
- the adhesive particles include prophylactic agents, such as ultraviolet (UV) light filters.
- UV ultraviolet
- the particles are applied topically. They can be used as or formulated in a sunscreen.
- the nanoparticles are useful in other topical applications, such as transdermal delivery of therapeutic, diagnostic, nutraceutical and/or prophylactic agents.
- FIG. 1A is a schematic of bioadhesive PLA-HPG ALD .
- FIG. 1B is a schematic showing the synthesis of stealth nanoparticles and sticky nanoparticles.
- FIG. 2 is a graph showing dye retention (%) of PLA-HPG and PLA-PEG nanoparticles as a function of incubation time in PBS.
- 3C is a graph of relative fluorescence (%) obtained from sections of pig skin incubated with DiD-loaded PLA-HPG ALD NPs (bioadhesive nanoparticles, BNPs) and DiD-loaded PLA-HPG NPs (non-bioadhesive nanoparticles, NNPs) at 1 mg/ml for 6 hours in a humidity chamber at 32° C.
- FIG. 4A is a graph showing percent retention (%) of PLA-HPG ALD NPs encapsulating an infrared dye, IR-780, as a function of time (days) following application to the dorsal skin of mice.
- FIG. 4B is a graph showing percent retention (%) of PLA-HPG ALD NPs encapsulating an infrared dye, IR-780, as a function of treatment with towel (T) or water (W). After washing with water or wiping with a wet towel, the PLA-HPG ALD NPs skin retention was imaged with Xenogen. The fluorescence was quantified and normalized to the fluorescence intensity at the starting point.
- DHR dihydrorhodamine
- BNPs bioadhesive nanoparticles
- PO/BNPs PLA-HPG ALD NPs encapsulating PO
- PBS phosphate buffered saline
- PO padamate O
- PVA polyvinyl alcohol.
- FIG. 7A is a bar graph showing epidermal thickness (microns) after receiving different topical interventions.
- FIG. 7B is a bar graph showing normalized percent area of keratin within the dorsal skin after receiving different interventions.
- the interventions were: A) Normal skin, B) Sunscreen, C) PO/PLA-HPG ALD NPs, D) blank PLA-HPG ALD NPs, and E) No treatment.
- PO/BNP bioadnesive nanoparticles (PLA-HPG ALD NPs) encapsulating PO, PO—padamate O.
- BNP bioadhesive nanoparticles
- ⁇ H2AX phosphorylated histone H2AX
- PO/BNP bioadhesive nanoparticles (PLA-HPG ALD NPs) encapsulating PO
- PO padamate O.
- FIGS. 10A, 10B, and 10C are diagrams comparing application of commercial sunscreen (Sunscreen) to PLA-HPG ALD NP (BNPs)-based sunscreen (BNPs/UV filters).
- FIG. 10A is a diagram of sunscreen formulations applied onto the skin.
- FIG. 10B is a diagram of the skin after application: regular sunscreen penetrates into the skin whereas the PLA-HPG ALD NP (BNPs) formulation remains on the stratum corneum.
- FIG. 10C is a diagram of the skin after sunlight exposure: UV filters produce deleterious ROS, however, PLA-HPG ALD NPs (BNPs) do not penetrate into the skin and prevent ROS mediated toxicity by confining these toxic products within the particle.
- BNP bioadhesive nanoparticles (PLA-HPG ALD NPs)
- UV ultraviolet.
- Effective amount or “therapeutically effective amount”, as used herein, refers to an amount of drug effective to alleviate, delay onset of, or prevent one or more symptoms of a disease or disorder.
- treating can include preventing a disease, disorder or condition from occurring in an animal which may be predisposed to the disease, disorder and/or condition but has not yet been diagnosed as having it; inhibiting the disease, disorder or condition, e.g., impeding its progress; and relieving the disease, disorder, or condition, e.g., causing regression of the disease, disorder and/or condition.
- Treating the disease, disorder, or condition can include ameliorating at least one symptom of the particular disease, disorder, or condition, even if the underlying pathophysiology is not affected, such as treating the pain of a subject by administration of an analgesic agent even though such agent does not treat the cause of the pain.
- Topical administration means the non-invasive administration to the skin, orifices, or mucosa. Topical administrations can be administered locally, i.e. they are capable of providing a local effect in the region of application without systemic exposure. Topical formulations can provide systemic effect via adsorption into the blood stream of the individual. Topical administration can include, but is not limited to, cutaneous and transdermal administration, buccal administration, intranasal administration, intravaginal administration, intravesical administration, ophthalmic administration, and rectal administration.
- bioactive agent and “active agent”, as used interchangeably herein, include, without limitation, physiologically or pharmacologically active substances that act locally or systemically in the body.
- a bioactive agent is a substance used for the treatment (e.g., therapeutic agent), prevention (e.g., prophylactic agent), diagnosis (e.g., diagnostic agent), cure or mitigation of disease or illness, a substance which affects the structure or function of the body, or pro-drugs, which become biologically active or more active after they have been placed in a predetermined physiological environment.
- Biocompatible and “biologically compatible”, as used herein, generally refer to materials that are, along with any metabolites or degradation products thereof, generally non-toxic to the recipient, and do not cause any significant adverse effects to the recipient.
- biocompatible materials are materials which do not elicit a significant inflammatory or immune response when administered to a patient.
- biodegradable generally refers to a material that will degrade or erode under physiologic conditions to smaller units or chemical species that are capable of being metabolized, eliminated, or excreted by the subject.
- the degradation time is a function of composition and morphology. Degradation times can be from hours to weeks.
- pharmaceutically acceptable refers to compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problems or complications commensurate with a reasonable benefit/risk ratio, in accordance with the guidelines of agencies such as the Food and Drug Administration.
- a “pharmaceutically acceptable carrier”, as used herein, refers to all components of a pharmaceutical formulation which facilitate the delivery of the composition in vivo.
- Pharmaceutically acceptable carriers include, but are not limited to, diluents, preservatives, binders, lubricants, disintegrators, swelling agents, fillers, stabilizers, and combinations thereof.
- molecular weight generally refers to the mass or average mass of a material. If a polymer or oligomer, the molecular weight can refer to the relative average chain length or relative chain mass of the bulk polymer. In practice, the molecular weight of polymers and oligomers can be estimated or characterized in various ways including gel permeation chromatography (GPC) or capillary viscometry. GPC molecular weights are reported as the weight-average molecular weight (M w ) as opposed to the number-average molecular weight (M n ). Capillary viscometry provides estimates of molecular weight as the inherent viscosity determined from a dilute polymer solution using a particular set of concentration, temperature, and solvent conditions.
- small molecule generally refers to an organic molecule that is less than about 2000 g/mol in molecular weight, less than about 1500 g/mol, less than about 1000 g/mol, less than about 800 g/mol, or less than about 500 g/mol. Small molecules are non-polymeric and/or non-oligomeric.
- copolymer generally refers to a single polymeric material that is comprised of two or more different monomers.
- the copolymer can be of any form, such as random, block, graft, etc.
- the copolymers can have any end-group, including capped or acid end groups.
- Hydrophilic refers to the property of having affinity for water.
- hydrophilic polymers or hydrophilic polymer segments
- hydrophilic polymer segments are polymers (or polymer segments) which are primarily soluble in aqueous solutions and/or have a tendency to absorb water.
- hydrophilic a polymer the more hydrophilic a polymer is, the more that polymer tends to dissolve in, mix with, or be wetted by water.
- Hydrophobic refers to the property of lacking affinity for, or even repelling water. For example, the more hydrophobic a polymer (or polymer segment), the more that polymer (or polymer segment) tends to not dissolve in, not mix with, or not be wetted by water.
- Hydrophilicity and hydrophobicity can be spoken of in relative terms, such as, but not limited to, a spectrum of hydrophilicity/hydrophobicity within a group of polymers or polymer segments.
- hydrophobic polymer can be defined based on the polymer's relative hydrophobicity when compared to another, more hydrophilic polymer.
- lipophilic refers to compounds having an affinity for lipids.
- amphiphilic refers to a molecule combining hydrophilic and lipophilic (hydrophobic) properties.
- Nanoparticle generally refers to a particle having a diameter, such as an average diameter, from about 10 nm up to but not including about 1 micron, preferably from 100 nm to about 1 micron.
- the particles can have any shape. Nanoparticles having a spherical shape are generally referred to as “nanospheres”.
- Microparticle generally refers to a particle having a diameter, such as an average diameter, from about 1 micron to about 100 microns, preferably from about 1 to about 50 microns, more preferably from about 1 to about 30 microns, most preferably from about 1 micron to about 10 microns.
- the microparticles can have any shape. Microparticles having a spherical shape are generally referred to as “microspheres”.
- Mean particle size as used herein, generally refers to the statistical mean particle size (diameter) of the particles in a population of particles.
- the diameter of an essentially spherical particle may refer to the physical or hydrodynamic diameter.
- the diameter of a non-spherical particle may refer preferentially to the hydrodynamic diameter.
- the diameter of a non-spherical particle may refer to the largest linear distance between two points on the surface of the particle.
- Mean particle size can be measured using methods known in the art, such as dynamic light scattering.
- “Monodisperse” and “homogeneous size distribution”, are used interchangeably herein and describe a population of nanoparticles or microparticles where all of the particles are the same or nearly the same size.
- a monodisperse distribution refers to particle distributions in which 90% or more of the distribution lies within 15% of the median particle size, more preferably within 10% of the median particle size, most preferably within 5% of the median particle size.
- Branch point refers to a portion of a polymer-drug conjugate that serves to connect one or more hydrophilic polymer segments to one or more hydrophobic polymer segments.
- targeting moiety refers to a moiety that binds to or localizes to a specific locale.
- the moiety may be, for example, a protein, nucleic acid, nucleic acid analog, carbohydrate, or small molecule.
- the locale may be a tissue, a particular cell type, or a subcellular compartment.
- the targeting moiety or a sufficient plurality of targeting moieties may be used to direct the localization of a particle or an active entity.
- the active entity may be useful for therapeutic, prophylactic, or diagnostic purposes.
- reactive coupling group refers to any chemical functional group capable of reacting with a second functional group to form a covalent bond.
- the selection of reactive coupling groups is within the ability of the skilled artisan.
- Examples of reactive coupling groups can include primary amines (—NH 2 ) and amine-reactive linking groups such as isothiocyanates, isocyanates, acyl azides, NHS esters, sulfonyl chlorides, aldehydes, glyoxals, epoxides, oxiranes, carbonates, aryl halides, imidoesters, carbodiimides, anhydrides, and fluorophenyl esters.
- reactive coupling groups can include aldehydes (—COH) and aldehyde reactive linking groups such as hydrazides, alkoxyamines, and primary amines.
- reactive coupling groups can include thiol groups (—SH) and sulfhydryl reactive groups such as maleimides, haloacetyls, and pyridyl disulfides.
- reactive coupling groups can include photoreactive coupling groups such as aryl azides or diazirines.
- the coupling reaction may include the use of a catalyst, heat, pH buffers, light, or a combination thereof.
- protective group refers to a functional group that can be added to and/or substituted for another desired functional group to protect the desired functional group from certain reaction conditions and selectively removed and/or replaced to deprotect or expose the desired functional group.
- Protective groups are known to the skilled artisan. Suitable protective groups may include those described in Greene, T. W. and Wuts, P. G. M., Protective Groups in Organic Synthesis, (1991). Acid sensitive protective groups include dimethoxytrityl (DMT), tert-butylcarbamate (tBoc) and trifluoroacetyl (tFA).
- Base sensitive protective groups include 9-fluorenylmethoxycarbonyl (Fmoc), isobutyrl (iBu), benzoyl (Bz) and phenoxyacetyl (pac).
- Other protective groups include acetamidomethyl, acetyl, tert-amyloxycarbonyl, benzyl, benzyloxycarbonyl, 2-(4-biphcnylyl)-2-propy!oxycarbonyl, 2-bromobenzyloxycarbonyl, tert-butyl 7 tert-butyloxycarbonyl, 1-carbobenzoxamido-2,2.2-trifluoroethyl, 2,6-dichlorobenzyl, 2-(3,5-dimethoxyphenyl)-2-propyloxycarbonyl, 2,4-dinitrophenyl, dithiasuccinyl, formyl, 4-methoxybenzenesulfonyl, 4-methoxybenzy
- the core of the particles is formed of or contains one or more hydrophobic materials, typically polymers (e.g., homopolymer, copolymer, terpolymer, etc.).
- the material may be biodegradable or non-biodegradable.
- the one or more materials are one or more biodegradable polymers.
- synthetic polymers are preferred, although natural polymers may be used and have equivalent or even better properties, especially some of the natural biopolymers which degrade by hydrolysis, such as some of the polyhydroxyalkanoates.
- Representative synthetic polymers are: poly(hydroxy acids) such as poly(lactic acid), poly(glycolic acid), and poly(lactic acid-co-glycolic acid), poly(lactide), poly(glycolide), poly(lactide-co-glycolide), polyanhydrides, polyorthoesters, polyamides, polycarbonates, polyalkylenes such as polyethylene and polypropylene, polyalkylene glycols such as poly(ethylene glycol), polyalkylene oxides such as poly(ethylene oxide), polyalkylene terepthalates such as poly(ethylene terephthalate), polyvinyl alcohols, polyvinyl ethers, polyvinyl esters, polyvinyl halides such as poly(vinyl chloride), polyvinylpyrrolidone, polysiloxa
- Examples of preferred natural polymers include proteins such as albumin, collagen, gelatin and prolamines, for example, zein, and polysaccharides such as alginate, cellulose derivatives and polyhydroxyalkanoates, for example, polyhydroxybutyrate.
- proteins such as albumin, collagen, gelatin and prolamines, for example, zein
- polysaccharides such as alginate, cellulose derivatives and polyhydroxyalkanoates, for example, polyhydroxybutyrate.
- derivatives include polymers having substitutions, additions of chemical groups and other modifications routinely made by those skilled in the art.
- non-biodegradable polymers examples include ethylene vinyl acetate, poly(meth)acrylic acid, polyamides, copolymers and mixtures thereof.
- the hydrophobic polymer is an aliphatic polyester.
- the hydrophobic polymer is poly(lactic acid), poly(glycolic acid), or poly(lactic acid-co-glycolic acid).
- the particles are designed to release molecules to be encapsulated or attached over a period of days to weeks. Factors that affect the duration of release include pH of the surrounding medium (higher rate of release at pH 5 and below due to acid catalyzed hydrolysis of PLGA) and polymer composition. Aliphatic polyesters differ in hydrophobicity and that in turn affects the degradation rate.
- the hydrophobic poly (lactic acid) (PLA), more hydrophilic poly (glycolic acid) PGA and their copolymers, poly (lactide-co-glycolide) (PLGA) have different release rates.
- the degradation rate of these polymers, and often the corresponding drug release rate, can vary from days (PGA) to months (PLA) and is easily manipulated by varying the ratio of PLA to PGA.
- the core can be formed of copolymers including amphiphilic copolymers such as PLGA-PEG or PLURONICS (block copolymers of polyethylene oxide-polypropylene glycol) but this may decrease the benefit of the polyglycerol molecules discussed below.
- lipids may also be incorporated including lipids, fatty acids, and phospholipids. These may be dispersed in or on the particles, or interspersed with the polyglycerol coatings discussed below.
- the particles include a shell or coating containing hyperbranched polyglycerol (HPG).
- HPG hyperbranched polyglycerol
- Hyperbranched polyglycerol is a highly branched polyol containing a polyether scaffold.
- Hyperbranched polyglycerol can be prepared using techniques known in the art. It can be formed from controlled etherification of glycerol via cationic or anionic ring opening multibranching polymerization of glycidol. For example, an initiator having multiple reactive sites is reacted with glycidol in the presence of a base to form hyperbranched polyglycerol (HPG).
- HPG hyperbranched polyglycerol
- Suitable initiators include, but are not limited to, polyols, e.g., triols, tetraols, pentaols, or greater and polyamines, e.g., triamines, tetraamines, pentaamines, etc.
- the initiator is 1,1,1-trihydroxymethyl propane (THP).
- o, p and q are independently integers from 1-100, wherein A 1 and A 2 are independently
- n and m are independently integers from 1-100.
- a 3 and A 4 are defined as A 1 and A 2 , with the proviso that A 3 and A 4 are hydrogen, n and m are each 1 for terminal residues.
- the surface properties of the HPG can be adjusted based on the chemistry of vicinal diols.
- the surface properties can be tuned to provide stealth particles, i.e., particles that are not cleared by the MPS due to the presence of the hydroxyl groups; adhesive (sticky) particles, i.e., particles that adhere to the surface of tissues, for example, due to the presence of one or more reactive functional groups, such as aldehydes, amines, oxime, or O-substituted oxime that can be prepared from the vicinal hydroxyl moieties; or targeting by the introduction of one or more targeting moieties which can be conjugated directly or indirectly to the vicinal hydroxyl moieties.
- FIG. 1A shows bioadhesive polymer.
- the hyperbranched nature of the polyglycerol allows for a much higher density of hydroxyl groups, reactive functional groups, and/or targeting moieties than obtained with linear polyethylene glycol.
- the particles can have a density of surface functionality (e.g., hydroxyl groups, reactive functional groups, and/or targeting moieties) of at least about 1, 2, 3, 4, 5, 6, 7, or 8 groups/nm 2 .
- the molecular weight of the HPG can vary.
- the molecular weight can vary depending on the molecular weight and/or hydrophobicity of the core materials.
- the molecular weight of the HPG is generally from about 1,000 to about 1,000,000 Daltons, from about 1,000 to about 500,000 Daltons, from about 1,000 to about 250,000 Daltons, or from about 1,000 to about 100,000 Daltons.
- the weight percent of HPG of the copolymer is from about 1% to about 50%, such as about 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50%.
- the HPG is covalently coupled to a hydrophobic material or a more hydrophobic material, such as a polymer.
- a hydrophobic material such as a polymer.
- particles are formed containing a core containing the hydrophobic material and a shell or coating of HPG.
- HPG coupled to the polymer PLA is shown below:
- the particles may contain one or more types of molecules encapsulated within and/or attached to the surface of the particles.
- the molecules can be covalently or non-covalently associated with the particles.
- the molecules are pigments or particles blocking or filtering ultraviolet (“UV”) radiation.
- UV ultraviolet
- the molecules are targeting moieties which are covalently associated with the particles.
- the targeting moieties are covalently bound to the HPG coating via the hydroxy groups on HPG.
- the targeting moieties can be bound directly to HPG or via a coupling agent.
- the particles have encapsulated therein one or more therapeutic agents, diagnostic agents, prophylactic agents, and/or nutraceuticals.
- the particles contain both targeting agents which are covalently or non-covalently associated with the particles and one or more therapeutic agents, diagnostic agents, prophylactic agents, and/or nutraceuticals which are covalently or non-covalently associated with the particles.
- Molecules can be bound to the hydroxy groups on HPG before or after particle formation. Representative methodologies for conjugated molecules to the hydroxy groups on HPG are described below.
- One useful protocol involves the “activation” of hydroxyl groups with carbonyldiimidazole (CDI) in aprotic solvents such as DMSO, acetone, or THF.
- CDI forms an imidazolyl carbamate complex with the hydroxyl group which may be displaced by binding the free amino group of a ligand such as a protein.
- the reaction is an N-nucleophilic substitution and results in a stable N-alkylcarbamate linkage of the ligand to the polymer.
- the “coupling” of the ligand to the “activated” polymer matrix is maximal in the pH range of 9-10 and normally requires at least 24 hrs.
- the resulting ligand-polymer complex is stable and resists hydrolysis for extended periods of time.
- Another coupling method involves the use of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDAC) or “water-soluble CDI” in conjunction with N-hydroxylsulfosuccinimide (sulfo NHS) to couple the exposed carboxylic groups of polymers to the free amino groups of ligands in a totally aqueous environment at the physiological pH of 7.0.
- EDAC and sulfo-NHS form an activated ester with the carboxylic acid groups of the polymer which react with the amine end of a ligand to form a peptide bond.
- the resulting peptide bond is resistant to hydrolysis.
- the use of sulfo-NHS in the reaction increases the efficiency of the EDAC coupling by a factor often-fold and provides for exceptionally gentle conditions that ensure the viability of the ligand-polymer complex.
- a useful coupling procedure for attaching ligands with free hydroxyl and carboxyl groups to polymers involves the use of the cross-linking agent, divinylsulfone. This method would be useful for attaching sugars or other hydroxylic compounds with bioadhesive properties to hydroxylic matrices.
- the activation involves the reaction of divinylsulfone to the hydroxyl groups of the polymer, forming the vinylsulfonyl ethyl ether of the polymer.
- the vinyl groups will couple to alcohols, phenols and even amines.
- Activation and coupling take place at pH 11. The linkage is stable in the pH range from 1-8.
- the hydroxyl groups can be converted to reactive functional group that can react with a reactive functional group on the molecule to be attached.
- the hydroxyl groups on HPG can be converted to aldehydes, amines, or O-substituted oximes which can react with reactive functional groups on molecules to be attached. Such transformations can be done before or after particle formation.
- Coupling is preferably by covalent binding but it may also be indirect, for example, through a linker bound to the polymer or through an interaction between two molecules such as strepavidin and biotin. It may also be by electrostatic attraction by dip-coating.
- the coupling methods can be done before or after particle formation.
- Ultraviolet light filters such as zinc oxide (ZnO), titanium dioxide (TiO2), avobenzone, tinosorb S, mexoryl SX, mexoryl XL, helioplex, octinoxate, octocrylene, oxybenzone, octisalate, homosalate, uvinul T 150, cinoxate, aminobenzoic acid, padimate O, ensulizole, dioxybenzone, meradimate, sulisobenzone, trolamine salicylate, enzacamene, bisdisulizole disodium, uvinul A Plus, uvasorb HEB, parsol SLX, amiloxate), antibiotics, antiseptics, antifungals, and anesthetic compounds (such as lidocaine, benzocaine, chloroprocaine, cyclomethycaine, dimethocaine/larocaine, piperocaine, propoxycaine, procaine/
- Prophylactic compounds can also include other components commonly used in lotions, creams and gels, such as fragrances, glycerol, petroleum jelly, dyes, preservatives, proteins, stabilizing agents, ferric oxide (Fe 2 O 3 ), zinc carbonate, or mixtures thereof.
- Prophylactic agents can also include antioxidants. Exemplary antioxidants include, but are not limited to, alpha tocopherol, ascorbic acid, acorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, monothioglycerol, potassium metabisulfite, propionic acid, propyl gallate, sodium ascorbate, sodium bisulfite, sodium metabisulfite, and sodium sulfite.
- UV filters such as padimate O (PO), zinc oxide (ZnO), titanium dioxide (TiO 2 ), silicon oxide coated ZnO or TiO 2 , avobenzone, tinosorb S, mexoryl SX, mexoryl XL, helioplex, octinoxate, octocrylene, oxybenzone, octisalate, homosalate, uvinul T 150, cinoxate, aminobenzoic acid, ensulizole, dioxybenzone, meradimate, sulisobenzone, trolamine salicylate, enzacamene, bisdisulizole disodium, uvinul A Plus, uvasorb HEB, parsol SLX, and amiloxate.
- UV filters such as padimate O (PO), zinc oxide (ZnO), titanium dioxide (TiO 2 ), silicon oxide coated ZnO or TiO 2 , avobenzone, tinosorb S, me
- these agents may be used to prevent skin conditions and skin diseases.
- Active Agents Therapeutic Agents, Diagnostic Agents, Prophylactic Agents, and/or Nutraceuticals
- Additional agents to be delivered include therapeutic, nutritional, diagnostic, and prophylactic compounds. Proteins, peptides, carbohydrates, polysaccharides, nucleic acid molecules, and organic molecules, as well as diagnostic agents, can be delivered.
- the preferred materials to be incorporated are prophylactic agents, such as UV filters, anti-oxidants, anesthetics, corticosteroids, anti-acne agents, and vitamins. Other preferred materials to be incorporated are therapeutic agents.
- Therapeutic agents include antibiotics, antivirals, anti-parasites (helminths, protozoans), anti-cancer (referred to herein as “chemotherapeutics”, including cytotoxic drugs such as doxorubicin, cyclosporine, mitomycin C, cisplatin and carboplatin, BCNU, 5FU, methotrexate, adriamycin, camptothecin, epothilones A-F, and taxol), peptide drugs, anti-inflammatories, and nutraceuticals.
- chemotherapeutics including antibiotics, antivirals, anti-parasites (helminths, protozoans), anti-cancer (referred to herein as “chemotherapeutics”, including cytotoxic drugs such as doxorubicin, cyclosporine, mitomycin C, cisplatin and carboplatin, BCNU, 5FU, methotrexate, adriamycin, camptothecin, epoth
- diagnostic materials include paramagnetic molecules, fluorescent compounds, magnetic molecules, and radionuclides.
- Exemplary materials include, but are not limited to, metal oxides, such as iron oxide, metallic particles, such as gold particles, etc. Biomarkers can also be conjugated to the surface for diagnostic applications.
- Active agents may be formulated alone or with excipients or encapsulated on, in or incorporated into the microparticles or nanoparticles.
- Active agents include therapeutic, prophylactic, neutraceutical and diagnostic agents. Any suitable agent may be used. These include organic compounds, inorganic compounds, proteins, polysaccharides, nucleic acids or other materials that can be incorporated using standard techniques.
- radioactive materials such as Technetium99 ( 99m Tc) or magnetic materials such as Fe 2 O 3 could be used.
- examples of other materials include gases or gas emitting compounds, which are radioopaque.
- the biodegradable polymers may encapsulate cellular materials, such as for example, cellular materials to be delivered to antigen presenting cells as described below to induce immunological responses.
- DNA-mediated immunity is needed to detect and destroy virus-infected cells.
- Most traditional vaccines e.g. protein-based vaccines
- DNA-based vaccine represents a unique means to vaccinate against a virus or parasite because a DNA based vaccine can induce both humoral and cell-mediated immunity.
- DNA-based vaccines are potentially safer than traditional vaccines.
- DNA vaccines are relatively more stable and more cost-effective for manufacturing and storage.
- DNA vaccines consist of two major components—DNA carriers (or delivery vehicles) and DNAs encoding antigens. DNA carriers protect DNA from degradation, and can facilitate DNA entry to specific tissues or cells and expression at an efficient level.
- the HPG coated particles can be modified to facilitate targeting or adhesion through the attachment of targeting molecules.
- target molecules include proteins, peptides, nucleic acids, lipids, saccharides, or polysaccharides, or small molecules that bind to one or more targets associated with an organ, tissue, cell, or extracellular matrix.
- a targeting moiety can be a polypeptide, such as an antibody that specifically recognizes a cell marker that is present exclusively or in higher amounts on a target cell (e.g., a keratinocyte cell antigen).
- Targeting molecules can be covalently bound to particles using a variety of methods known in the art.
- the targeting moieties are covalently associated with the polymer, preferably via a linker cleaved at the site of delivery.
- the nanoparticles can contain one or more polymer conjugates containing end-to-end linkages between the polymer and a targeting element or a detectable label.
- a modified polymer can be a PLA-HPG-peptide block polymer.
- targeting moieties include peptides such as iRGD, LyP1; small molecule such as folate, aptamers and antibodies, such as antibodies to integrins or skin cell receptors, or their combinations at various molar ratios.
- the targeting element of the nanoparticle can be an antibody or antigen binding fragment thereof.
- the targeting elements should have an affinity for a cell-surface receptor or cell-surface antigen on the target cells and result in binding of the particle to the target cell.
- the target molecule can be a cell surface polypeptide, lipid, or glycolipid.
- Cell specific markers can be for specific types of cells including, but not limited to stem cells, skin cells, follicle cells, and infected skin cells.
- the cell markers can be specific for endothelial, ectodermal, or mesenchymal cells.
- Representative cell specific markers include, but are not limited to cancer specific markers.
- the targeting element can be a peptide.
- the plaque targeted peptide can be, but is not limited to, one or more of the following: RGD, iRGD(CRGDK/RGPD/EC), LyP-1, P3(CKGGRAKDC), or their combinations at various molar ratios.
- the targeting peptides can be covalently associated with the polymer and the covalent association can be mediated by a linker.
- the targeting element can be an antibody or an antigen-binding fragment thereof.
- the antibody can be any type of immunoglobulin that is known in the art.
- the antibody can be of any isotype, e.g., IgA, IgD, IgE, IgG, IgM, etc.
- the antibody can be monoclonal or polyclonal.
- the antibody can be a naturally-occurring antibody, e.g., an antibody isolated and/or purified from a mammal, e.g., mouse, rabbit, goat, horse, chicken, hamster, human, etc.
- the antibody can be a genetically-engineered antibody, e.g., a humanized antibody or a chimeric antibody.
- the antibody can be in monomeric or polymeric form.
- the antigen binding portion of the antibody can be any portion that has at least one antigen binding site, such as Fab, F(ab′) 2 , dsFv, sFv, diabodies, and triabodies.
- the antibody is a single chain antibody.
- Aptamers are oligonucleotide or peptide sequences with the capacity to recognize virtually any class of target molecules with high affinity and specificity. Aptamers bind to targets such as small organics, peptides, proteins, cells, and tissues. Unlike antibodies, some aptamers exhibit stereoselectivity. The aptamers can be designed to bind to specific targets expressed on cells, tissues or organs.
- the outer surface of the particle may be treated using a mannose amine, thereby mannosylating the outer surface of the particle. This treatment may cause the particle to bind to the target cell or tissue at a mannose receptor on the antigen presenting cell surface.
- surface conjugation with an immunoglobulin molecule containing an Fc portion targeting Fc receptor
- HSP receptor heat shock protein moiety
- phosphatidylserine scavenger receptors
- LPS lipopolysaccharide
- any positively charged ligand such as polyethyleneimine or polylysine
- any particle may improve bioadhesion due to the electrostatic attraction of the cationic groups coating the beads to the net negative charge of the mucus.
- Any ligand with a high binding affinity for mucin could also be covalently linked to most microparticles with the appropriate chemistry.
- polyclonal antibodies raised against components of mucin or else intact mucin, when covalently coupled to particles, would provide for increased bioadhesion.
- the ligand affinity need not be based only on electrostatic charge, but other useful physical parameters such as solubility in mucin or else specific affinity to carbohydrate groups.
- polyamino acids containing extra pendant carboxylic acid side groups e.g., polyaspartic acid and polyglutamic acid
- polyamino acids containing extra pendant carboxylic acid side groups e.g., polyaspartic acid and polyglutamic acid
- polyamino acids in the 15,000 to 50,000 kDa molecular weight range would yield chains of 120 to 425 amino acid residues attached to the surface of the particles.
- the polyamino chains would increase bioadhesion by means of chain entanglement in mucin strands as well as by increased carboxylic charge.
- the HPG-coated particles can be modified by covalently attaching PEG to the surface. This can be achieved by converting the vicinyl diol groups to aldehydes and then reacting the aldehydes with functional groups on PEG, such as aliphatic amines, aromatic amines, hydrazines and thiols.
- the linker has end groups such as aliphatic amines, aromatic amines, hydrazines, thiols and O-substituted oxyamines.
- the bond inserted in the linker can be disulfide, orthoester and peptides sensitive to proteases.
- PEG with a functional group or a linker can form a bond with aldehyde on PLA-HPGALD and reversed the bioadhesive(sticky) state of PLA-HPGALD to stealth state.
- This bond or the linker is labile to pH change or high concentration of peptides, proteins and other biomolecules.
- the bond attaching the PEG to PLA-HPGALD can be reversed or cleaved to release the PEG in response to environment and exposed the PLA-HPGALD particles to the environment. Subsequently, the particles will interact with the tissue and attach the particles to the tissues or extracellular materials such as proteins.
- the environment can be acidic environment in tumors, reducing environment in tumors, protein rich environment in tissues.
- microencapsulation techniques include, but are not limited to, spray drying, interfacial polymerization, hot melt encapsulation, phase separation encapsulation (spontaneous emulsion microencapsulation, solvent evaporation microencapsulation, and solvent removal microencapsulation), coacervation, low temperature microsphere formation, and phase inversion nanoencapsulation (PIN).
- the particles are prepared using an emulsion-based technique.
- the particles are prepared using a double emulsion solvent evaporation technique.
- the amphiphilic material and the hydrophobic cationic material are dissolved in a suitable organic solvent, such as methylene chloride or dichloromethane (DCM), with or without agent to be encapsulated.
- a suitable organic solvent such as methylene chloride or dichloromethane (DCM)
- phase separation microencapsulation techniques a polymer solution is stirred, optionally in the presence of one or more active agents to be encapsulated. While continuing to uniformly suspend the material through stirring, a nonsolvent for the polymer is slowly added to the solution to decrease the polymer's solubility. Depending on the solubility of the polymer in the solvent and nonsolvent, the polymer either precipitates or phase separates into a polymer rich and a polymer poor phase. Under proper conditions, the polymer in the polymer rich phase will migrate to the interface with the continuous phase, encapsulating the active agent(s) in a droplet with an outer polymer shell.
- Spontaneous emulsification involves solidifying emulsified liquid polymer droplets formed above by changing temperature, evaporating solvent, or adding chemical cross-linking agents.
- One or more active agents to be incorporated are optionally added to the solution, and the mixture is suspended in an aqueous solution that contains a surface active agent such as poly(vinyl alcohol).
- a surface active agent such as poly(vinyl alcohol).
- the resulting emulsion is stirred until most of the organic solvent evaporated, leaving solid microparticles/nanoparticles. This method is useful for relatively stable polymers like polyesters and polystyrene.
- Nanoparticles can also be formed using the phase inversion nanoencapsulation (PIN) method, wherein a polymer is dissolved in a “good” solvent, fine particles of a substance to be incorporated, such as a drug, are mixed or dissolved in the polymer solution, and the mixture is poured into a strong non solvent for the polymer, to spontaneously produce, under favorable conditions, polymeric microspheres, wherein the polymer is either coated with the particles or the particles are dispersed in the polymer.
- PIN phase inversion nanoencapsulation
- Nanoparticles can be prepared using microfluidic devices.
- a polymeric material is mixed with a drug or drug combinations in a water miscible organic solvent.
- the water miscible organic solvent can be one or more of the following: acetone, ethanol, methanol, isopropyl alcohol, acetonitrile and Dimethyl sulfoxide (DMSO).
- DMSO Dimethyl sulfoxide
- Hyperbranched polyglycerol can be covalently bound to one or more materials, such as a polymer, that form the core of the particles using methodologies known in the art.
- HPG can be covalently coupled to a polymer having carboxylic acid groups, such as PLA, PGA, or PLGA using DIC/DMAP.
- the HPG can be initiated from special functionalized initiators to facilitate the conjugation to more materials. These special initiators include disulfide (Yeh et al., Langmuir. 24(9):4907-16(2008)).
- the HPG can be functionalized to introduce one or more reactive functional groups that alter the surface properties of the particles.
- HPG-coated particles prevent non-specific adsorption of serum proteins and increase the blood circulation of the particles.
- Such particles are referred to as stealth particle.
- the hydroxyl groups on HPG can be chemically modified to cause the particles to stick to biological material, such as tissues, organs, cells, etc.
- Such functional groups include aldehydes, amines, O-substituted oximes, and combinations thereof.
- a synthetic scheme for such chemical conversions is shown in FIG. 1 .
- the surface of the particles can further be modified with one or more targeting moieties or covalently bound to HPG via a coupling agent or spacer in organic solvents such as dichloromethane (DCM), dimethylformamide (DMF), dimethyl sulfoxide (DMSO) or tetrahydrofuran (THF).
- DCM dichloromethane
- DMF dimethylformamide
- DMSO dimethyl sulfoxide
- THF tetrahydrofuran
- the polymer is functionalized/modified before nanoparticle formation.
- the targeting moieties may be attached to NPs after the synthesis of NPs in aqueous solution (or other protic solution such as alcohol).
- HPG coated NPs can be transformed to aldehyde terminated NPs by NaIO 4 treatment (or carboxylic acid terminated by NaIO 4 treatment followed by sodium chlorite treatment) so the targeting moieties may be directly covalently attached to NPs via aldehyde (or carboxylic acid) groups on NPs and functional groups (amine, hydrazine, aminooxy and their derivatives) on the targeting moieties or indirectly attached to the NPs via coupling agents or spacers (such as aminooxy modified biotin and cysteine).
- NaIO 4 treatment or carboxylic acid terminated by NaIO 4 treatment followed by sodium chlorite treatment
- the targeting moieties may be directly covalently attached to NPs via aldehyde (or carboxylic acid) groups on NPs and functional groups (amine, hydrazine, aminooxy and their derivatives) on the targeting moieties or indirectly attached to the NPs via coupling agents or spacers (such as aminooxy modified biotin and cysteine).
- Certain properties of the PLA-HPG conjugate are important for the observed effects. Because high molecular weight HPG has better resistance of non-specific adsorption to biomolecules, the low molecular weight components are removed from the synthesized HPG by multiple solvent precipitations and dialysis.
- a polyhydroxy acid such as PLA is selected as the hydrophobic core material because it is biodegradable, has a long history of clinical use, and is the major component of a NP system that is advancing in clinical trials.
- the previous approach was to first functionalize the HPG with an amine and then conjugate the carboxylic group on PLA to the amine. This approach is efficient but cannot be used to make HPG as surface coatings since any amines that do not react with PLA will lead to a net positive charge on the neutral HPG surface and reduce the ability of HPG to resist adsorption of other molecules on the surface.
- the approach in the examples uses a one-step esterification between PLA and HPG, which maintained the charge neutral state of the HPG.
- Targeting molecules or agents to be encapsulated or delivered may be associated with the surface of, encapsulated within, surrounded by, and/or distributed throughout the polymeric matrix of the particles.
- the particles may have any zeta potential.
- the particles can have a zeta potential from ⁇ 300 mV to +300 mV, ⁇ 100 mV to +100 mV, from ⁇ 50 mV to +50 mV, from ⁇ 40 mV to +40 mV, from ⁇ 30 mV to +30 mV, from ⁇ 20 mV to +20 mV, from ⁇ 10 mV to +10 mV, or from ⁇ 5 mV to +5 mV.
- the particles can have a negative or positive zeta potential.
- the particles have a substantially neutral zeta potential, i.e. the zeta potential is approximately 0 mV.
- the particles have a zeta potential of approximately ⁇ 30 to about 30 mV, preferably from about ⁇ 20 to about 20 mV, more preferably from about ⁇ 10 to about 10 mV.
- the particles may have any diameter.
- the particles can have a diameter of about 1 nm to about 1000 microns, about 1 nm to about 100 microns, about 1 nm to about 10 microns, about 1 nm to about 1000 nm, about 1 nm to about 500 nm, about 1 nm to about 250 nm, or about 1 nm to about 100 nm.
- the particle is a nanoparticle having a diameter from about 25 nm to about 250 nm.
- the particles are nanoparticles having a diameter from about 180 nm to about 250 nm, preferably from about 180 nm to about 230 nm.
- the polydispersity is from about 0.05 to 0.30, preferably from about 0.05 to about 0.25, more preferably from about 0.05 to about 0.20, more preferably from about 0.05 to about 0.15, most preferably from about 0.05 to about 0.10.
- the particles can be formulated with appropriate pharmaceutically acceptable carriers into pharmaceutical compositions for administration to an individual in need thereof.
- the formulations can be administered topically (e.g., to the skin via non-invasive topical application).
- Other routes of administration include, but are not limited to, transdermal.
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, one or more polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), oils, such as vegetable oils (e.g., peanut oil, corn oil, sesame oil, etc.), and combinations thereof.
- polyols e.g., glycerol, propylene glycol, and liquid polyethylene glycol
- oils such as vegetable oils (e.g., peanut oil, corn oil, sesame oil, etc.)
- the proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and/or by the use of surfactants.
- isotonic agents for example, sugars or sodium chloride.
- Solutions and dispersions of the active compounds as the free acid or base or pharmacologically acceptable salts thereof can be prepared in water or another solvent or dispersing medium suitably mixed with one or more pharmaceutically acceptable excipients including, but not limited to, surfactants, dispersants, emulsifiers, pH modifying agents, viscosity modifying agents, and combination thereof.
- Suitable surfactants may be anionic, cationic, amphoteric or nonionic surface active agents.
- Suitable anionic surfactants include, but are not limited to, those containing carboxylate, sulfonate and sulfate ions.
- anionic surfactants include sodium, potassium, ammonium of long chain alkyl sulfonates and alkyl aryl sulfonates such as sodium dodecylbenzene sulfonate; dialkyl sodium sulfosuccinates, such as sodium dodecylbenzene sulfonate; dialkyl sodium sulfosuccinates, such as sodium bis-(2-ethylthioxyl)-sulfosuccinate; and alkyl sulfates such as sodium lauryl sulfate.
- Cationic surfactants include, but are not limited to, quaternary ammonium compounds such as benzalkonium chloride, benzethonium chloride, cetrimonium bromide, stearyl dimethylbenzyl ammonium chloride, polyoxyethylene and coconut amine.
- nonionic surfactants include ethylene glycol monostearate, propylene glycol myristate, glyceryl monostearate, glyceryl stearate, polyglyceryl-4-oleate, sorbitan acylate, sucrose acylate, PEG-150 laurate, PEG-400 monolaurate, polyoxyethylene monolaurate, polysorbates, polyoxyethylene octylphenylether, PEG-1000 cetyl ether, polyoxyethylene tridecyl ether, polypropylene glycol butyl ether, POLOXAMER® 401, stearoyl monoisopropanolamide, and polyoxyethylene hydrogenated tallow amide.
- amphoteric surfactants include sodium N-dodecyl-.beta.-alanine, sodium N-lauryl-.beta.-iminodipropionate, myristoamphoacetate, lauryl betaine and lauryl sulfobetaine.
- the formulation can contain a preservative to prevent the growth of microorganisms. Suitable preservatives include, but are not limited to, parabens, chlorobutanol, phenol, benzalkonium, sorbic acid, and thimerosal.
- Suitable preservatives include, but are not limited to, parabens, chlorobutanol, phenol, benzalkonium, sorbic acid, and thimerosal.
- the formulation may also contain an antioxidant to prevent degradation of the active agent(s).
- the formulation is typically buffered to a pH of 3-8.
- Suitable buffers include, but are not limited to, phosphate buffers, acetate buffers, and citrate buffers.
- Water soluble polymers may be used in formulations. Suitable water-soluble polymers include, but are not limited to, polyvinylpyrrolidone, dextran, carboxymethylcellulose, and polyethylene glycol.
- Carrier also includes all components of the coating composition which may include plasticizers, pigments, colorants, stabilizing agents, and glidants.
- Formulations can be prepared using one or more topical or pharmaceutically acceptable excipients, including diluents, preservatives, binders, lubricants, disintegrators, swelling agents, fillers, stabilizers, and combinations thereof.
- Stabilizers are used to inhibit or retard drug decomposition reactions which include, by way of example, oxidative reactions.
- Suitable stabilizers include, but are not limited to, antioxidants, butylated hydroxytoluene (BHT); ascorbic acid, its salts and esters; Vitamin E, tocopherol and its salts; sulfites such as sodium metabisulphite; cysteine and its derivatives; citric acid; propyl gallate, and butylated hydroxyanisole (BHA).
- the particles can be used for a variety of applications including protecting tissue from UV light, drug delivery, tissue engineering, etc.
- the particles are “stealth” particles, where the hydroxyl groups on HPG resist non-specific protein absorption. This can allow targeted particles to be delivered to the desired site for drug release. Such stealth properties can also be useful for topical delivery, for example, diffusion into hair follicles to release agents to promote hair growth/prevent hair loss or agents that promote hair loss.
- the vicinyl diol groups can be converted to functional groups that adhere to biological materials, such as tissue (e.g., cornea), organs (e.g., skin), cells, proteins, etc. Such particles are referred to as “sticky”.
- the particles can be used to deliver one or more therapeutic agents, diagnostic agents, prophylactic agents, nutraceuticals, or combinations thereof to the skin.
- the vicinyl diol groups on HPG can be chemically transformed to functional groups that make the particle adhere or stick to tissue or other biological materials, such as skin (e.g., sticky particles).
- Incubation of HPG-coated particles with the reagent NaIO 4 which converts vicinyl diol groups to aldehyde groups, showed an estimated 8 aldehyde groups/nm 2 after about 20 minutes.
- Surface immobilization of HPG particles on lysine-coated slides increased as the incubation time with NaIO 4 increased.
- Aldehyde-functionalized HPG-coated particles loaded with the dye DiD were incubated with pig skin for 6 hours.
- the relative fluorescence of the aldehyde-functionalized particles was three-fold higher than the relative fluorescence of HPG-coated particles.
- the particles can be used for delivery of one or more active agents to the skin.
- the particles can be used as or formulated in a sunscreen.
- the particles were loaded with padimate O (PO), an organic compound used in suncreens. Under conditions mimicking the pH range of human sweat (4.5 and 7.4), the particles retained more than about 96% of the PO after 20 hours. The particles also exhibited improved UV absorption compared to PO dispersed in water or aqueous buffer.
- PO padimate O
- agents for treating skin aging include agents for treating skin aging, such as anti-reactive oxygen species (ROS) therapies.
- ROS anti-reactive oxygen species
- the particles can also be used to deliver agents to hair follicles, for examples, agents to promote hair growth or reduce hair loss or therapies to remove hair.
- agents to hair follicles for examples, agents to promote hair growth or reduce hair loss or therapies to remove hair.
- the stealth nature of the particles can allow diffusion of the particles into the hair follicles.
- a chronic wound is a wound that does not heal normally. Wounds that do not heal within three months are often considered chronic.
- One embodiment provides administering an effective amount of the particles to a chronic wound to promote or enhance healing.
- the disclosed particles can also be used to treat fibrotic wounds.
- Fibrotic wounds have dysregulated healing and typically delayed healing. Fibrosis can be defined as the replacement of the normal structural elements of the tissue by distorted, non-functional and excessive accumulation of scar tissue.
- One embodiment provides a method for treating fibrotic wounds by administering an effective amount of the disclosed particles to promote or enhance fibrotic wound healing.
- the particles can also be used with wound dressings.
- a wound dressing having a layer of particles on the wound dressing.
- the layer of particles is configured to come into contact with the wound when the wound dressing is applied to a wound.
- the particles can be impregnated in the wound dressing or coated on the wound dressing using conventional techniques.
- the wound dressing can be made of absorbent materials such as cotton or fleece.
- the wound dressing can also be made of synthetic fibers, for example, polyamide fibers.
- the wound dressing can have multiple layers including an adhesive layer, an absorbent layer, and moisture regulation layer.
- the wound dressing can also include antimicrobial agents, antifungal agents, and other active agents to promote wound healing such as cytokines and growth factors discussed above.
- Another embodiment provides a method for treating a wound by administering an effective amount of the disclosed particles to the wound to promote or induce hemostasis and then applying a wound dressing to the wound.
- Ligands can be selected to enhance the particles being retained at the site, by binding to extracellular matrix or through non-specific electrostatic binding.
- H 2 N-PEG(5000)-OCH 3 was obtained from Laysan.
- Anhydrous dimethylformide, dichloromethane, diisopropylcarboimide, dimethylaminopyridie, potassium methoxide, camptothecin, polyvinyl alcohol, paraformaldehyde, TWEEN® 80, and 1,1,1-trihydroxymethyl propane were obtained from the Sigma-Aldrich.
- Microdialysis tubing was from Thermo Scientific.
- IR-780 iodide, hydroxylamine solution (50%), glycerol, polyvinyl alcohol, NaIO4 and bovine serum albumin (BSA) were obtained from the Sigma-Aldrich.
- Donkey normal serum and Rabbit-anti-CD31 antibody was provided by Abcam and the Donkey-anti-rabbit secondary antibody tagged with Alexa488 fluorophore was from Invitrogen.
- Aldehyde Quantification Assay Kit (Fluorometric) and were from Abcam.
- Sunscreen lotion (SPF 30) was purchased from Walgreens.
- Sunscreen oil (SPF 30) was from L'Oréal Paris.
- Hyperbranched polyglycerol was synthesized by anionic polymerization. Briefly, 4.6 mmol 1,1,1-trihydroxypropane (THP) was added into an argon protected flask in a 95° C. oil bath and 1.5 mmol KOCH 3 was added. The system was hooked up to a vacuum pump and left under vacuum for 30 min. The system was refilled with argon and 25 ml glycidol was added by a syringe pump over 12 hours. The HPG was dissolved in methanol and precipitated by addition of acetone. HPG was purified 2-3 times with methanol/acetone precipitation.
- HPG low molecular weight HPG
- 2-5 ml HPG was placed in a 10 ml dialysis tube (0.5-1 k cut-off) and dialyzed against deionized (DI) water. The water was replaced two times every 12 hours. HPG was precipitated with acetone and then dried under vacuum at 80° C. for 12 h.
- DI deionized
- PLA (5 g) and 2.15 g HPG were dissolved in dimethyl formamide (DMF) and dried over molecular sieves overnight. 0.06 ml diisopropylcarboimide (DIC) and 10 mg 4-(N,N-dimethylamino)pyridine (DMAP) were added and the reaction proceeded for 5 days at room temperature under stirring. The product was precipitated by pouring the reaction into cold diethyl ether (ether) and collecting the precipitate by centrifugation. The product was redissolved in dichloromethane (DCM) and precipitated again with a cold mixture of ether and methanol. The product was washed with a cold mixture of ether and methanol. The polymer was dried under vacuum for 2 days.
- DCM dichloromethane
- PLA-PEG 2.6 g PLA and 1.0 g MPEG-NH 2 were dissolved in DMF and dried over molecular sieves overnight. 0.038 ml DIC was added and the reaction proceeded for 2 days at room temperature under stirring. The product was precipitated by pouring the reaction into cold ether and collecting the precipitate by centrifugation. The product was redissolved in DCM and precipitated again with cold ether, washed with a cold mixture of ether and methanol and dried under vacuum for 2 days.
- NPs Nanoparticles
- the PLA-PEG NPs were made using a single emulsion technique. 50 mg PLA-PEG copolymer dissolved in 1.5-3.0 ml ethyl acetate/DMSO (4:1) was added to 4 ml DI water with 2.5% PVA under vortexing and subjected to probe sonication for 3 cycles of 10 sec each. The resulting emulsion was diluted in 20 ml DI water with 0.1% Tween® 80 with stirring. The emulsion was stirred for at least 5 hours or attached to a ratovapor to evaporate the ethyl acetate and then the solution was applied to an Amico ultra centrifuge filtration unit (100 k cut-off). The NPs were washed by filtration for 2 times then suspended in a 10% sucrose solution.
- NPs Nanoparticles
- TEM Transmission Electron Microscopy
- the NPs were characterized with TEM. A drop of nanoparticle suspension was applied on the top of carbon coated copper grids and most of the droplet was removed with a piece of filter paper. The thin layer of NPs suspension was dried for 5-10 min and then a droplet of uranyl acetate was applied. Most of the droplet was removed with a filter paper and left to dry for 5 min. The sample was mounted for imaging with TEM. The size distribution of NPs was analyzed in Image J. The hydrodynamic size of NPs was determined by dynamic laser scattering (DLS). NPs suspension was diluted with DI water to 0.05 mg/ml and 1 ml was loaded into the cell for detection.
- DLS dynamic laser scattering
- DMSO dimethyl methacrylate
- concentration of the dye in NPs 990 ⁇ L DMSO was added to 10 ⁇ L NPs in aqueous solution. The solution was vortexed and left in the dark for 10 min. The concentration of the dye was quantified with a plate reader by fluorescence of the DiD dye at 670 nm with an excitation wavelength at 644 nm.
- the DP n (number-average degree of polymerization) for HPG was calculated according to the inverse gated 13 C NMR spectra for HPG with the following equation:
- Mn Molecular weight of glycidol ⁇ DP n of HPG+molecular weight of TMP
- Both particles have a biodegradable PLA core, which can be used to load hydrophobic agents, and a hydrophilic shell of HPG or PEG.
- HPG was made by anionic polymerization and characterized by 1 H NMR and 13 C NMR.
- PLA-HPG copolymer was synthesized by esterification and the conjugation of PLA-HPG was confirmed by 1 H NMR.
- the weight percentage of HPG in PLA-HPG was about 29% as calculated from the NMR results.
- PLA-HPG NPs were made from a single emulsion as described above.
- PLA-PEG copolymer was synthesized by the conjugation of PLA-COOH with amine terminated mPEG and also characterized with 1 H NMR. The weight percentage of PEG was about 26% as calculated from the NMR results.
- TEM Transmission electronic microscopy confirmed the spherical shape of the PLA-HPG and PLA-PEG NPs.
- the hydrodynamic diameter of NPs was 100 nm as measured by dynamic light scattering (DLS) (Table 1).
- Microdialysis tubes were filled with 100 ⁇ L of NPs loaded with 1,1′-dioctadecyl-3,3,3,3′,3′-tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate Salt (DiD) and placed on a floater in a large beaker with 4 L PBS at 37° C. Tubes were removed in triplicates at different time points. The PBS was changed every 12 hours. The dye left in the dialysis tube was quantified by fluorescence.
- DID 4-chlorobenzenesulfonate Salt
- DiD-loaded NPs release a minimal amount of dye ( ⁇ 20%) over 5 days of continuous incubation in PBS ( FIG. 2 ). Both PLA-HPG and PLA-PEG NPs were loaded with equivalent amounts of DiD.
- PLA-HPG NPs (0.1 mg/ml) in a 96-well plate (small vial) were incubated with 1 mM NaIO 4 and at each time point, the reactions were quenched with 2 mM Na 2 SO 3 .
- the NPs were washed two times with DI water in an AcroPrep filter plate with 100 k cut-off (or amicon ultra filter 0.5 ml with 100 k cut-off) and then suspended in DI water.
- the aldehydes on NPs were quantified with an aldehyde quantification assay kit (Abcam).
- the PLA-HPG NPs were used as a background subtraction control.
- the amount of aldehyde was calculated by comparing to a reference curve.
- the reference curve was made by using the aldehyde standard provided with the kit.
- the amount of aldehyde on each particle was calculated based on 100 nm hydrodynamic diameter of NPs and an assumed NP density of 1.0 g/cm 3 .
- NPs load with DiD dye were suspended in PBS buffer containing 15% glycerol and 0.01% triton-X100 at a concentration of 1 mg/ml in a 384-well plate.
- the NPs were arrayed on lysine coated slides using a Spotbot microrrayer from Arrayit. After 1 hour incubation in a humidity chamber, the printed slides were washed extensively with PBS 3 times, 5 min each. After a quick rinse with DI water, the slides were blow-dried with argon and subjected for imaging.
- the NPs were transferred to an AcroPrep filter plate with 100 k cut-off (or amicon ultra filter 0.5 ml with 100 k cut-off or gel filtration for proteins and other large molecules) and washed two times with DI water or buffer.
- PLA-HPG ALD NPs dipy, also referred to herein as bioadhesive nanoparticles, BNPs
- PLA-HPG NPs also referred to herein as non-bioadhesive nanoparticles, NNPs
- PLA-HPG ALD NPs could be reversed to PLA-HPG Reversed (stealth) NPs by NaBH 4 treatment, though one alcohol group is lost with the reduction-reversal cycle since each vicinal diol on HPG is oxidized by NaIO 4 to an aldehyde and each aldehyde is reduced to a single alcohol by NaBH 4 .
- the blood circulation confirmed that the PLA-HPG ALD NPs lost almost all their stickiness after treatment with NaBH 4 .
- the back and forth tunability also demonstrated the robustness of the HPG coating on the nanoparticles.
- PLA-HPG ALD NPs PLA-HPG ALD NPs
- PLA-HPG ALD NPs with different concentrations of aldehydes were prepared using a high-throughput procedure, where regular 96-well plates and 96-well filter plates were used to prepare the NPs and printed onto polylysine coated slides with a microarrayer.
- the PLA-HPG NPs (NNPs) without NaIO 4 treatment did not adhere to glass slides and only background signal was detected.
- the amount of NPs immobilized on the glass slide increased as a function of duration of NaIO 4 treatment, indicating that the bioadhesive property of the PLA-HPG NPs can be tuned by control of NaIO 4 treatment.
- NPs load with DiD dye were suspended in PBS buffer containing 15% glycerol and 0.01% TRITON®-X100 at a concentration of 1 mg/ml in a 384-well plate.
- the NPs were arrayed on lysine coated slides using a SPOTBOT® microrrayer from ARRAYIT®. After 1 hour incubation in a humidity chamber, the printed slides were washed extensively with PBS 3 times, 5 min each. After a quick rinse with DI water, the slides were blow-dried with argon and subjected for imaging.
- the bioadhesive property of PLA-HPG NPs on tissues was evaluated by applying suspended NPs ex vivo to the external surface of pig skin.
- Fresh pig skin was obtained from a local slaughterhouse and the hair was carefully removed by a trimmer, making sure no damage occurred to the skin.
- the skin was frozen at ⁇ 20° C.
- the skin was thawed on ice before use.
- Thawed pig skin was washed with PBS buffer and cut to 2 ⁇ 2 cm pieces.
- DiD-loaded PLA-HPG NPs (NNPs) and PLA-HPG ALD NPs (BNPs) in PBS were topically applied to pig skin and incubated for 6 h in a humidity chamber at 32° C. After incubation, skin was washed with plenty of PBS buffer and frozen in OCT.
- the frozen skin was sectioned into 10-20 ⁇ m slices, mounted on glass slides, and imaged with an EVOS fluorescence microscope.
- PLA-HPG ALD NPs showed greater retention on pig skin than PLA-HPG NPs (P ⁇ 0.05).
- the fluorescence intensity was quantified from the fluorescence images.
- PLA-HPG NPs can be readily oxidized to aldehyde-terminated PLA-HPG ALD NPs by sodium periodate (NaIO4) treatment. This was validated by H 1 NMR and Schiffs agent analysis.
- the surface density of aldehydes on PLA-HPG ALD NPs was monitored as a function of incubation time with NaIO 4 and it reached its saturation at about 20 min ( FIG. 3A ).
- the final surface density of aldehydes on PLA-HPG ALD NPs approached 9/nm 2 (17 aldehydes/PLA molecule), indicating that the majority of surface vicinal diols were converted to aldehydes.
- This surface density of functional groups is at least one order of magnitude higher than previously reported on biodegradable NPs (Gu et al., Proc. Natl. Acad. Sci. U.S.A. 105:2586-2591 (2008)). Moreover, the surface density of the aldehydes can be controlled by incubation time with NaIO 4 . No detrimental effects of aldehyde conversion were observed on NPs by TEM imaging. The average diameter of NPs was approximately 96 nm by dynamic light scattering (DLS) measurement (Table 2).
- PLA-HPG ALD NPs PLA-HPG ALD NPs
- PLA-HPG ALD NPs PLA-HPG ALD NPs
- NNPs PLA-HPG NPs
- Nanoparticles Diameter (nm) PDI PLA-HPG ALD 96 0.273 DiD/PLA-HPG 120 0.211 DiD/PLA-HPG ALD 118 0.232 IR-780/PLA-HPG ALD 128 0.334 PO/PLA-HPG ALD 138 0.227
- Delivery vehicles for UV-filters should ideally remain only on the skin surface, without penetration into the epidermis, dermis, or hair follicles, in order to avoid potential health risks (Krause, et al., Int. J. Androl. 35:424-436 (2012)).
- the retention and the penetration of PLA-HPG ALD NPs ex vivo to PLA-HPG NPs by applying suspended particles topically onto pig skin was compared.
- both NPs were loaded with a hydrophobic dye, 0.2%1,1′-dioctadecyl-3,3,3′,3′-tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate salt (DiD) (Deng et al., Biomaterials. 35:6595-6602 (2014)).
- DiD/PLA-HPG NPs and DiD/PLA-HPG ALD NPs were characterized by TEM and DLS (Table 2), and had a similar spherical morphology.
- PLA-HPG ALD NPs showed substantially higher retention on pig skin compared to NNPs ( FIG. 3C ).
- No penetration of PLA-HPG ALD NPs was observed on any pig skin samples; however, PLA-HPG NPs penetrated into the pig skin follicles without significant retention on the stratum corneum.
- Pig skin is considered a good mimic for human skin in a variety of applications including penetration studies for chemicals and nanoparticles (Swindle et al., Veterinary Pathology 49:738-738 and 344 (2012); Barbero et al., Toxicol. In Vitro 23:1-13 (2009)).
- PLA-HPG ALD NPs exhibit no skin penetration whereas the PLA-HPG NPs exhibit considerable penetration into follicles, reflect the adhesion of PLA-HPG ALD NPs to proteins on the skin surface, which prevents diffusion of nanoparticles to deeper skin layer or into follicles.
- the water resistance and potential for removal of PLA-HPG ALD NPs by encapsulating an infrared dye, IR-780, into BNPs (0.5% loading), and measuring nanoparticle skin concentrations with in vivo imaging was investigated.
- the IR-780/PLA-HPG ALD NPs were characterized by TEM and DLS (Table 2). After extensive washing with water, no significant change in fluorescence was observed; however, the PLA-HPG ALD NPs were removed after wiping with a wet towel ( FIGS. 4A and 4B ). If untreated, PLA-HPG ALD NPs concentration diminished markedly (approximately 75%) within 24 hr and disappearance was essentially complete after five days ( FIG. 5A ).
- PLA-HPG ALD NPs will interact with tissues since the bioadhesive property of PLA-HPG ALD NPs is resulted from the Schiff-base bond between the aldehyde groups on PLA-HPG ALD NPs and the amine groups in tissue surface.
- PLA-HPG ALD NPs can simplify the current sunscreen formulation as well as eliminate the use of irritants and/or allergens.
- PLA-HPG ALD NPs are ideal vehicles for sunscreen application since they are water-soluble but their interaction with skin is water-resistant.
- the PLA-HPG ALD NPs disappear from skin naturally by exfoliation of the stratum corneum; removal can be accelerated mechanically by towel drying.
- PLA-HPG polymer and PO an organic compound used in sunscreens
- ratio ratio from 1:1 to 20:1 and total mass of 50-100 mg
- the resulting emulsion was diluted in 20 ml DI water with stirring. It was hooked up to a rotovapor to evaporate the ethyl acetate and then applied to an Amico ultra centrifuge filtration unit (100 k cut-off).
- the PO/PLA-HPG NPs were washed by filtration 2 times then suspended in DI water.
- the same procedure was implemented to produce PLA-HPG ALD NPs, as PO/PLA-HPG ALD NPs can be oxidized from PO/PLA-HPG NPs nanoparticles.
- the nanoparticles were dissolved in DMSO and the UV absorbance at 310 nm was measured with a plate reader. The amount of PO was calculated by comparing to a reference curve.
- All PO/PLA-HPG ALD NPs contained 10% PO.
- the spherical shape of the PO/BNPs was confirmed by TEM.
- a hydrodynamic diameter of 138 nm for PO/PLA-HPG ALD NPs was measured by DLS. The results for hydrodynamic diameter of all the NPs generated in these studies are presented in Table 2.
- the stability of PO encapsulation in NPs was evaluated by measuring the release of PO in buffer mimicking the pH range (4.5-7.4) of human sweat.
- a suspension of 1 mg NPs loaded with PO in a dialysis tube (10K cut-off) was dialyzed against 40 ml PBS with 0.1% SDS at 32° C. At each time point, 150 ⁇ L solution was removed and 150 ⁇ L PBS with 0.1% SDS was added. The amount of released PO was quantified by UV adsorption at 310 nm with a plate reader.
- PLA-HPG ALD NPs loaded with PO retained more than about 96% of the PO after 20 hours.
- the particles also exhibited improved UV absorption compared to PO dispersed in water or aqueous buffer.
- UV filters prevent sunburn by absorbing UV radiation. Therefore, their effectiveness can be estimated by measuring their UV absorption efficiency.
- Photoinduced changes in UV filters often produce toxic intermediates including ROS that are destructive to multiple cellular components including gDNA (Hanson et al., Free Radical Biology and Medicine, 41:1205-1212 (2006)). It has been reported that encapsulating UV filters in polymeric nanoparticles improves filter photostability and delays photodegradation of the UV filters (Perugini et al., International Journal of Pharmaceutics, 246:37-45 (2002)).
- PO/PLA-HPG ALD NPs suspended in water, PO emulsified in water and PO dissolved in mineral oil at a PO concentration of 0.01 mg/ml were aliquoted into a UV transparent plate and scanned through the UV absorbance spectrum from 260-400 nm with a plate reader. Blank PLA-HPG ALD NPs, water and mineral oil were also scanned as background controls.
- the PO emulsion in water was made by probe sonication.
- PO/PLA-HPG ALD NPs, PLA-HPG ALD NPs, PO water emulsion at a PO concentration of 0.1 mg/ml was incubated with DHR in 96 well plate. After exposing to UV-B (280-320 nm), plate fluorescence was read at Ex/Em 500/536 nm.
- DHR Dihydrarhodamine
- ROS probe Hanson et al., Free Radical Biology and Medicine, 41:1205-1212 (2006)
- DHR was mixed with PO/PLA-HPG ALD NPs, emulsified PO, and PLA-HPG ALD NPs separately and exposed to UV.
- DHR in PBS was used as a control because it absorbs UV at 280-315 nm and becomes fluorescent.
- PO/PLA-HPG ALD NPs were compared to PO emulsified in polyvinyl alcohol (PVA) solution (PO/PVA), PO in mineral oil (PO/oil), sunscreen (L'Oreal sunscreen oil spray) in mineral oil (sunscreen/oil); blank PLA-HPG ALD NPs, mineral oil and PVA solution were used as controls ( FIG. 6A ). All solutions contained equivalent PO concentrations (0.01 mg/ml). PO/PLA-HPG ALD NPs showed a 20-fold higher absorption compared to the PO emulsion in PVA solution and sunscreen diluted in mineral oil (active ingredients adjusted to 0.01 mg/ml) after background subtraction of the appropriate base material ( FIG. 6B ).
- the PO/PVA emulsion is a simplified, representative version of a sunscreen formulation (Allured, Cosmet Toiletries, 99:79-79 (1984)); most current sunscreens are based on an emulsion of UV filters (Tanner, Dermatologic Clinics, 24:53-62 (2006)).
- the sunscreen oil used in this example is an oil spray with the same active ingredients and SPF value as the sunscreen lotion used in the animal studies.
- the PLA-HPG ALD NPs had a negligible effect on the background fluorescence of DHR as measured by the control since they did not absorb UV.
- the fluorescence from the PO suspension is much higher than the control ( FIG. 6C ). It is believed that the free ROS generated from the photoactivated PO after UV exposure oxidized the DHR into fluorescent species. In contrast, by confining the ROS within NPs, the PO/PLA-HPG ALD NPs significantly decreased the background fluorescence.
- mice were anesthetized with Ketamine/Xylazine, and their dorsal skin was cleaned with 70% alcohol and demarcated into four quadrants. One quadrant was used as a PBS control and other areas were treated with sunscreen, PO/PLA-HPG ALD NPs or blank PLA-HPG ALD NPs. Only the dorsal epidermis was exposed to the UV lamp (UV-A and UV-B, 280-400 nm, 8 W) for one min (2160 J/m 2 ) and the remaining skin was covered with screens. The mice were left in separate cages and monitored until they woke up. Three days after UV exposure, the dorsal skin was removed and prepared for histology. Images were analyzed for epidermal thickness and keratin content using ImageJ.
- the UV filter (PO) concentration in PO/PLA-HPG ALD NPs was less than 5% of that contained in the sunscreen, yet the PO/PLA-HPG ALD NPs achieved a similar gross UV protection effect.
- Trichome staining was also employed to measure the anti-UV effect against sunburn ( FIG. 7B ).
- the skin protected by sunscreen showed thickened orthokeratosis, a more subtle epidermal response than to UV-damage, relative to the skin protected by PO/PLA-HPG ALD NPs and the normal skin control. Overproduction of keratin can cause keratosis pilaris, often blocking the opening of hair follicles and resulting in further skin irritation. These results may therefore also demonstrate another non-irritating benefit of sunblock based on PLA-HPG ALD NPs.
- mice The dorsal hair of FVB mice was shaved with electric clippers and treated with depilatory cream. One week later, the mice received either
- PO/PLA-HPG ALD NPs sunscreen, or no treatment followed by dorsal exposure to UV (160 J/m2) one hour after treatment.
- UV 160 J/m2
- dorsal skin flaps were removed five minutes after UV exposure, and incubated in PBS containing 20 mM EDTA for 2 hours at 37° C. to allow separation of the epidermis from the dermis.
- the epidermal sheet was then rinsed in PBS, fixed in acetone for 20 min at ⁇ 20° C., then permeabilized in cold PBS containing 0.5% Triton X-100 for 30 min.
- Sheets were denatured with 0.4 M NaOH in 70% ethanol for 22 min and then washed with cold PBS containing 0.5% Triton X-100 four times, eight min each. Sheets were blocked with PBS containing 2% BSA, 0.5% Triton-X-100 and 1% goat serum for one hour at room temp, then stained overnight at 4° C. with anti-thymine dimer (2 mg/ml, Abcam #ab 10347) and diluted in PBS containing 0.4% BSA and 0.5% Triton X-100.
- the ⁇ H2AX+ cells were counted using ImageJ particle analyzer software with the threshold set to eliminate the very faint ⁇ H2AX staining.
- the surface concentration of ⁇ H2AX+ cells was calculated by dividing the overall number of the ⁇ H2AX+ cells on a sheet with the surface area of the sheet.
- DSBs induced by UV irradiation are highly carcinogenic. UVB exposure does not directly produce DSBs (Bastien et al., The Journal of Investigative Dermatology, 130:2463-2471 (2010)); however, it is possible that UV filters present in the epidermis and dermis can produce ROS after photoactivation, react with cellular DNA, and ultimately produce DSBs (Gulston and Knowland, Mutat Res - Gen Tox En. 444:49-60 (1999); Hanson et al., Free Radical Biology and Medicine, 41:1205-1212 (2006); Bastien et al., The Journal of Investigative Dermatology, 130:2463-2471 (2010); Girard et al., J Phys Conf Ser.
- FIGS. 10A, 10B , and 10 C are diagrams comparing application of commercial sunscreen (Sunscreen) to PLA-HPG ALD NP (BNPs)-based sunscreen (BNPs/UV filters).
- FIG. 10A is a diagram of sunscreen formulations applied onto the skin.
- FIG. 10B is a diagram of the skin after application: regular sunscreen penetrates into the skin whereas the PLA-HPG ALD NP (BNPs) formulation remains on the stratum corneum.
- FIG. 10C is a diagram of the skin after sunlight exposure: UV filters produce deleterious ROS, however, PLA-HPG ALD NPs (BNPs) do not penetrate into the skin and prevent ROS mediated toxicity by confining these toxic products within the particle.
- the PLA-HPG ALD NPs sunblock demonstrated a durable and specific adherence to the stratum corneum, without any evidence of penetration into cellular components of the epidermis ( FIG. 10A ); a 20-fold greater UV spectral absorbance; superior protection against UV-induced CPDs and DSBs ( FIG. 10B ); and improved protection against UV-induced orthokeraosis ( FIG. 10C ).
- PLA-HPG ALD NPs on skin are water resistant, yet are easily removed with towel drying, or disappear naturally by exfoliation of the stratum corneum. Encapsulating UV filters within BNPs prevented skin exposure to the filter molecules, and the subsequent ROS produced after UV photochemical activation. With less than 5% UV filter encapsulation, the protective effect of PO/PLA-HPG ALD NPs against sunburn was comparable to commercial sunscreen in animal studies, and had the added benefit of preventing subsequent ROS mediated DSBs.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Birds (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Polymers & Plastics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
Abstract
Description
wherein 1, m and n are independently integers from 1-100.
wherein A3 and A4 are defined as A1 and A2, with the proviso that A3 and A4 are hydrogen, n and m are each 1 for terminal residues.
The functionality of the core molecule (TMP), fc, is 3.
The Mn of HPG is calculated with the following equation:
TABLE 1 |
Average diameter of PLA-HPG nanoparticles |
and PLA-PEG nanoparticles. |
NPs | Diameter (nm) | ||
PLA-HPG | 102.1 ± 3.1 | ||
PLA-PEG | 103.3 ± 1.0 | ||
TABLE 2 |
Diameter (nm) and polydispersity index (PDI) of various |
nanoparticles. |
Nanoparticles (NPs) | Diameter (nm) | PDI | ||
PLA- |
96 | 0.273 | ||
DiD/PLA- |
120 | 0.211 | ||
DiD/PLA-HPGALD | 118 | 0.232 | ||
IR-780/PLA-HPGALD | 128 | 0.334 | ||
PO/PLA-HPGALD | 138 | 0.227 | ||
Claims (22)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/379,224 US10758459B2 (en) | 2014-05-09 | 2019-04-09 | Topical formulation of hyperbranched polyglycerol-coated particles thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461991025P | 2014-05-09 | 2014-05-09 | |
PCT/US2015/030187 WO2015172153A1 (en) | 2014-05-09 | 2015-05-11 | Topical formulation of hyperbranched polyglycerol-coated particles thereof |
US201615309733A | 2016-11-08 | 2016-11-08 | |
US16/379,224 US10758459B2 (en) | 2014-05-09 | 2019-04-09 | Topical formulation of hyperbranched polyglycerol-coated particles thereof |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/309,733 Continuation US10272019B2 (en) | 2014-05-09 | 2015-05-11 | Topical formulation of hyperbranched polyglycerol-coated particles thereof |
PCT/US2015/030187 Continuation WO2015172153A1 (en) | 2014-05-09 | 2015-05-11 | Topical formulation of hyperbranched polyglycerol-coated particles thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
US20200000687A1 US20200000687A1 (en) | 2020-01-02 |
US10758459B2 true US10758459B2 (en) | 2020-09-01 |
Family
ID=54393090
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/309,733 Active 2035-06-29 US10272019B2 (en) | 2014-05-09 | 2015-05-11 | Topical formulation of hyperbranched polyglycerol-coated particles thereof |
US15/309,741 Active 2035-05-13 US10238581B2 (en) | 2014-05-09 | 2015-05-11 | Hyperbranched polyglycerol-coated particles and methods of making and using thereof |
US15/269,456 Active US10660828B2 (en) | 2014-05-09 | 2016-09-19 | Hyperbranched polyglycerol-coated particles and methods of making and using thereof |
US16/363,823 Active US11364182B2 (en) | 2014-05-09 | 2019-03-25 | Hyperbranched polyglycerol-coated particles and methods of making and using thereof |
US16/379,224 Active US10758459B2 (en) | 2014-05-09 | 2019-04-09 | Topical formulation of hyperbranched polyglycerol-coated particles thereof |
US16/882,000 Active 2035-07-12 US11826438B2 (en) | 2014-05-09 | 2020-05-22 | Hyperbranched polyglycerol-coated particles and methods of making and using thereof |
US17/842,376 Active US11896686B2 (en) | 2014-05-09 | 2022-06-16 | Hyperbranched polyglycerol-coated particles and methods of making and using thereof |
US18/514,738 Pending US20240173216A1 (en) | 2014-05-09 | 2023-11-20 | Hyperbranched polyglycerol-coated particles and methods of making and using thereof |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/309,733 Active 2035-06-29 US10272019B2 (en) | 2014-05-09 | 2015-05-11 | Topical formulation of hyperbranched polyglycerol-coated particles thereof |
US15/309,741 Active 2035-05-13 US10238581B2 (en) | 2014-05-09 | 2015-05-11 | Hyperbranched polyglycerol-coated particles and methods of making and using thereof |
US15/269,456 Active US10660828B2 (en) | 2014-05-09 | 2016-09-19 | Hyperbranched polyglycerol-coated particles and methods of making and using thereof |
US16/363,823 Active US11364182B2 (en) | 2014-05-09 | 2019-03-25 | Hyperbranched polyglycerol-coated particles and methods of making and using thereof |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/882,000 Active 2035-07-12 US11826438B2 (en) | 2014-05-09 | 2020-05-22 | Hyperbranched polyglycerol-coated particles and methods of making and using thereof |
US17/842,376 Active US11896686B2 (en) | 2014-05-09 | 2022-06-16 | Hyperbranched polyglycerol-coated particles and methods of making and using thereof |
US18/514,738 Pending US20240173216A1 (en) | 2014-05-09 | 2023-11-20 | Hyperbranched polyglycerol-coated particles and methods of making and using thereof |
Country Status (5)
Country | Link |
---|---|
US (8) | US10272019B2 (en) |
EP (4) | EP3721875B1 (en) |
ES (2) | ES2966886T3 (en) |
PL (2) | PL3140269T3 (en) |
WO (2) | WO2015172149A1 (en) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3721875B1 (en) | 2014-05-09 | 2023-11-08 | Yale University | Particles coated with hyperbranched polyglycerol and methods for their preparation |
US11918695B2 (en) | 2014-05-09 | 2024-03-05 | Yale University | Topical formulation of hyperbranched polymer-coated particles |
WO2016183217A1 (en) | 2015-05-11 | 2016-11-17 | Yale University | Functionalized polymeric particles for treatment of gliomas |
BR112018009644A2 (en) | 2015-11-12 | 2018-11-06 | Graybug Vision Inc | surface modified solid aggregate microparticles, injectable material, process for preparing surface modified solid aggregate microparticles, method for treating an eye disorder, and use of surface modified solid aggregate microparticles |
DE102016000533A1 (en) * | 2016-01-21 | 2017-07-27 | Beiersdorf Ag | New octocrylene-free sunscreen with diethylaminohydroxybenzylhexylbenzoate |
US11136597B2 (en) | 2016-02-16 | 2021-10-05 | Yale University | Compositions for enhancing targeted gene editing and methods of use thereof |
EP3429652A4 (en) * | 2016-03-17 | 2019-11-27 | Aushealth Corporate Pty Ltd | Medical devices using coated polymers |
EP3429651B1 (en) * | 2016-03-17 | 2022-12-21 | TekCyte Limited | Anti-fouling and/or anti-thrombotic medical devices |
AU2018240462C1 (en) | 2017-03-23 | 2022-12-08 | Graybug Vision, Inc. | Drugs and compositions for the treatment of ocular disorders |
US20200113821A1 (en) | 2017-04-04 | 2020-04-16 | Yale University | Compositions and methods for in utero delivery |
WO2018209155A1 (en) * | 2017-05-10 | 2018-11-15 | Graybug Vision, Inc. | Extended release microparticles and suspensions thereof for medical therapy |
US20210189431A1 (en) | 2018-08-10 | 2021-06-24 | Yale University | Compositions and methods for embryonic gene editing in vitro |
CN109608647B (en) * | 2018-12-25 | 2022-01-04 | 上海交通大学医学院 | Active oxygen responsive polymers, supports and uses thereof |
WO2020257779A1 (en) | 2019-06-21 | 2020-12-24 | Yale University | Hydroxymethyl-modified gamma-pna compositions and methods of use thereof |
US20220243211A1 (en) | 2019-06-21 | 2022-08-04 | Yale University | Peptide nucleic acid compositions with modified hoogsteen binding segments and methods of use thereof |
WO2021022161A1 (en) | 2019-07-31 | 2021-02-04 | Yale University | Compositions and methods for treating sickle cell disease |
WO2021050568A1 (en) * | 2019-09-09 | 2021-03-18 | Yale University | Nanoparticles for selective tissue or cellular uptake |
US20230086800A1 (en) * | 2020-03-06 | 2023-03-23 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody fragments conjugated to peg-plga nanoparticles improve immunotherapy against cancer cells |
JP2021147329A (en) * | 2020-03-16 | 2021-09-27 | 株式会社リコー | Method for producing particles |
CN111632196A (en) * | 2020-06-01 | 2020-09-08 | 内蒙古自治区中医药研究所 | Preparation method of acellular matrix for removing alpha-galactosyl antigen |
CN112126070B (en) * | 2020-08-27 | 2022-04-26 | 合肥飞木生物科技有限公司 | Hyperbranched polyglycerol ester polymer bio-based plasticizer and preparation method and application thereof |
WO2022165403A1 (en) * | 2021-02-01 | 2022-08-04 | Yale University | Chemotherapeutic bioadhesive particles with immunostimulatory molecules for cancer treatment |
EP4352226A1 (en) | 2021-06-07 | 2024-04-17 | Yale University | Peptide nucleic acids for spatiotemporal control of crispr-cas binding |
CN113975249B (en) * | 2021-10-14 | 2023-01-03 | 中山大学·深圳 | Preparation of Tris-BNP nano-particles and application thereof in treatment of skin diseases |
WO2023159114A2 (en) * | 2022-02-16 | 2023-08-24 | The Cleveland Clinic Foundation | Lymphatic delivery of nanoparticles to treat neurodegenerative, neurological, and eye conditions |
WO2023220067A1 (en) | 2022-05-09 | 2023-11-16 | Yale University | Immunotherapy of skin cancer using mpla-loaded hpg nanoparticles |
WO2024026041A1 (en) * | 2022-07-29 | 2024-02-01 | Board Of Trustees Of Michigan State University | Remote control and quantitative monitoring of drug release from nanoparticles based on magnetic particle imaging |
WO2024102876A1 (en) | 2022-11-10 | 2024-05-16 | Yale University | Intrathecal nanoparticle delivery for treatment of leptomeningeal tumors with core-shell particles made of hyperbranched polyglycerol and polylactic acid |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060105026A1 (en) | 2003-04-04 | 2006-05-18 | Fortune David H | Tissue-adhesive formulations |
US20110060036A1 (en) | 2008-03-29 | 2011-03-10 | Emory University | Branched Multifunctional Nanoparticle Conjugates And Their Use |
US20110200666A1 (en) | 2010-02-12 | 2011-08-18 | Rovi Cosmetics International Gmbh | UV PROTECTION AGENT FOR THE SKIN OR HAIR HAVING A UV FILTER SUBSTANCE ENCAPSULATED IN A VESICULAR CARRIER SYSTEMü |
US8206747B2 (en) | 2008-06-16 | 2012-06-26 | Bind Biosciences, Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
WO2012156094A1 (en) | 2011-05-18 | 2012-11-22 | Freie Universität Berlin | Nanoparticles functionalized with dendritic polyglycerol sulfate |
WO2013166487A1 (en) | 2012-05-04 | 2013-11-07 | Yale University | Highly penetrative nanocarriers for treatment of cns disease |
US8715736B2 (en) | 2009-04-30 | 2014-05-06 | Florida Agricultural And Mechanical University | Nanoparticle formulations for skin delivery |
WO2015172149A1 (en) | 2014-05-09 | 2015-11-12 | Yale University | Hyperbranched polyglycerol-coated particles and methods of making and using thereof |
US9492382B2 (en) | 2009-12-18 | 2016-11-15 | Basf Se | Hyperbranched polyester having a hydrophobic core for solubilizing active ingredients of low solubility |
Family Cites Families (107)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA149128A (en) | 1913-03-04 | 1913-07-08 | Melon James Trumle | Evaporator for petroleum oil |
GB929401A (en) | 1958-12-22 | 1963-06-19 | Upjohn Co | Encapsulated emulsions and processes for their preparation |
US3031928A (en) * | 1959-02-13 | 1962-05-01 | Baird Atomic Inc | Control of flexible surfaces by means of a probe |
GB969808A (en) | 1962-06-08 | 1964-09-16 | Boots Pure Drug Co Ltd | Anthelmintic compositions and compounds |
US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
US3832253A (en) | 1973-03-21 | 1974-08-27 | Baxter Laboratories Inc | Method of making an inflatable balloon catheter |
GB1413186A (en) | 1973-06-27 | 1975-11-12 | Toyo Jozo Kk | Process for encapsulation of medicaments |
IT1148784B (en) | 1980-04-09 | 1986-12-03 | Eurand Spa | PROCEDURE FOR THE PREPARATION OF MICRO CAPSULES IN A LIQUID VEHICLE |
US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
CA1200416A (en) | 1983-05-13 | 1986-02-11 | Societe Des Produits Nestle S.A. | Food process |
US4965204A (en) | 1984-02-06 | 1990-10-23 | The Johns Hopkins University | Human stem cells and monoclonal antibodies |
US4714680B1 (en) | 1984-02-06 | 1995-06-27 | Univ Johns Hopkins | Human stem cells |
US4794000A (en) | 1987-01-08 | 1988-12-27 | Synthetic Blood Corporation | Coacervate-based oral delivery system for medically useful compositions |
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US4667013A (en) | 1986-05-02 | 1987-05-19 | Union Carbide Corporation | Process for alkylene oxide polymerization |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
US5422251A (en) | 1986-11-26 | 1995-06-06 | Princeton University | Triple-stranded nucleic acids |
FR2608988B1 (en) | 1986-12-31 | 1991-01-11 | Centre Nat Rech Scient | PROCESS FOR THE PREPARATION OF COLLOIDAL DISPERSIBLE SYSTEMS OF A SUBSTANCE, IN THE FORM OF NANOPARTICLES |
US4883666A (en) | 1987-04-29 | 1989-11-28 | Massachusetts Institute Of Technology | Controlled drug delivery system for treatment of neural disorders |
US5114719A (en) | 1987-04-29 | 1992-05-19 | Sabel Bernhard A | Extended drug delivery of small, water-soluble molecules |
US5601835A (en) | 1987-04-29 | 1997-02-11 | Massachusetts Institute Of Technology | Polymeric device for controlled drug delivery to the CNS |
US6699475B1 (en) | 1987-09-02 | 2004-03-02 | Therion Biologics Corporation | Recombinant pox virus for immunization against tumor-associated antigens |
US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
KR920003787B1 (en) | 1990-03-05 | 1992-05-14 | 한국과학기술 연구원 | Method for producing igf-i |
US5061620A (en) | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
JPH04167172A (en) | 1990-10-31 | 1992-06-15 | Nec Corp | Vector processor |
US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
US6451968B1 (en) | 1991-05-24 | 2002-09-17 | Isis Pharmaceuticals, Inc. | Peptide nucleic acids |
US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
GB9126677D0 (en) | 1991-12-16 | 1992-02-12 | Johnson Matthey Plc | Improvements in chemical compounds |
US5487994A (en) | 1992-04-03 | 1996-01-30 | The Johns Hopkins University | Insertion and deletion mutants of FokI restriction endonuclease |
US5436150A (en) | 1992-04-03 | 1995-07-25 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease |
US5356802A (en) | 1992-04-03 | 1994-10-18 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease |
US5571711A (en) | 1993-06-17 | 1996-11-05 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors |
US5962426A (en) | 1993-06-25 | 1999-10-05 | Yale University | Triple-helix forming oligonucleotides for targeted mutagenesis |
ES2113118T3 (en) | 1993-06-25 | 1998-04-16 | Univ Yale | CHEMICALLY MODIFIED OLIGONUCLEOTIDE WITH A VIEW TO A SITE-DIRECTED MUTAGENESIS. |
US5527675A (en) | 1993-08-20 | 1996-06-18 | Millipore Corporation | Method for degradation and sequencing of polymers which sequentially eliminate terminal residues |
DE4331012A1 (en) | 1993-09-13 | 1995-03-16 | Bayer Ag | Nucleic acid-binding oligomers with N-branching for therapy and diagnostics |
US5409813A (en) | 1993-09-30 | 1995-04-25 | Systemix, Inc. | Method for mammalian cell separation from a mixture of cell populations |
GB9400411D0 (en) | 1994-01-11 | 1994-03-09 | Johnson Matthey Plc | Improvements in chemical compounds |
US5677136A (en) | 1994-11-14 | 1997-10-14 | Systemix, Inc. | Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof |
AU6043296A (en) | 1995-06-06 | 1996-12-24 | Yale University | Chemically modified oligonucleotide for site-directed mutage nesis |
AU6328696A (en) | 1995-06-07 | 1996-12-30 | Yale University | Treatment of hemoglobinopathies |
US7279463B2 (en) | 1995-06-07 | 2007-10-09 | Yale University | Triple-helix forming oligonucleotides for targeted mutagenesis |
US5821122A (en) | 1995-06-07 | 1998-10-13 | Inserm (Institute Nat'l De La Sante Et De La Recherche . .) | Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof |
US6143211A (en) | 1995-07-21 | 2000-11-07 | Brown University Foundation | Process for preparing microparticles through phase inversion phenomena |
US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
AU3585397A (en) | 1996-06-27 | 1998-01-14 | G.D. Searle & Co. | Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications |
US5945337A (en) | 1996-10-18 | 1999-08-31 | Quality Biological, Inc. | Method for culturing CD34+ cells in a serum-free medium |
US5786571A (en) | 1997-05-09 | 1998-07-28 | Lexmark International, Inc. | Wrapped temperature sensing assembly |
GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
US20030044978A1 (en) | 1998-02-05 | 2003-03-06 | Novartis Corporation | Expanded and genetically modified populations of human hematopoietic stem cells |
CA2341897A1 (en) | 1998-08-28 | 2000-03-09 | Uropath Pty. Ltd. | Method of diagnosis of prostate cancer |
US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
WO2000050900A2 (en) | 1999-02-26 | 2000-08-31 | Pacific Northwest Research Institute | Methods and compositions for diagnosing carcinomas |
WO2001000788A2 (en) | 1999-06-25 | 2001-01-04 | Northwestern University | Compositions, kits, and methods for modulating survival and differentiation of multi-potential hematopoietic progenitor cells |
US6919208B2 (en) | 2000-05-22 | 2005-07-19 | The Children's Hospital Of Philadelphia | Methods and compositions for enhancing the delivery of a nucleic acid to a cell |
US6673545B2 (en) | 2000-07-28 | 2004-01-06 | Incyte Corporation | Prostate cancer markers |
AU2001278143B2 (en) | 2000-08-02 | 2007-08-09 | Slil Biomedical Corporation | Cyclic polyamine compounds for cancer therapy |
US7067617B2 (en) | 2001-02-21 | 2006-06-27 | The Scripps Research Institute | Zinc finger binding domains for nucleotide sequence ANN |
US20040197892A1 (en) | 2001-04-04 | 2004-10-07 | Michael Moore | Composition binding polypeptides |
EP1421177A4 (en) | 2001-08-20 | 2006-06-07 | Scripps Research Inst | Zinc finger binding domains for cnn |
CA2470033A1 (en) | 2001-12-14 | 2003-06-26 | Yale University | Intracellular generation of single-stranded dna |
IL163875A0 (en) | 2002-03-07 | 2005-12-18 | Univ Delaware | Methods, compositions, and kits for enhancing oli gonucleotide mediated nucleic acid sequence alteration using compositions comprising a histone de |
TWI248947B (en) * | 2003-07-21 | 2006-02-11 | Ind Tech Res Inst | Biodegradable copolymer, and polymeric micelle composition containing the copolymer |
US20050055078A1 (en) * | 2003-09-04 | 2005-03-10 | Medtronic Vascular, Inc. | Stent with outer slough coating |
US7371781B2 (en) | 2003-09-22 | 2008-05-13 | University Of Utah Research Foundation | Tumor environment-induced ligand-expressing nanocarrier system |
US6984899B1 (en) | 2004-03-01 | 2006-01-10 | The United States Of America As Represented By The Secretary Of The Navy | Wind dam electric generator and method |
US20070072815A1 (en) | 2004-05-04 | 2007-03-29 | Kmiec Eric B | Methods and kits to increase the efficiency of oligonucleotide-directed nucleic acid sequence alteration |
CA2571899A1 (en) | 2004-07-01 | 2006-08-03 | Yale University | Targeted and high density drug loaded polymeric materials |
WO2007001448A2 (en) | 2004-11-04 | 2007-01-04 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
US8658608B2 (en) | 2005-11-23 | 2014-02-25 | Yale University | Modified triple-helix forming oligonucleotides for targeted mutagenesis |
JP2009520463A (en) | 2005-11-28 | 2009-05-28 | ザ スクリプス リサーチ インスティテュート | Zinc finger binding domain for TNN |
US20070154989A1 (en) | 2006-01-03 | 2007-07-05 | The Scripps Research Institute | Zinc finger domains specifically binding agc |
JP2008053276A (en) | 2006-08-22 | 2008-03-06 | Nec Electronics Corp | Method of manufacturing semiconductor device |
US20100172882A1 (en) | 2007-01-11 | 2010-07-08 | Glazer Peter M | Compositions and methods for targeted inactivation of hiv cell surface receptors |
US8889117B2 (en) | 2007-02-15 | 2014-11-18 | Yale University | Modular nanoparticles for adaptable vaccines |
US10265407B2 (en) | 2007-02-15 | 2019-04-23 | Yale University | Modular nanodevices for smart adaptable vaccines |
WO2008109347A2 (en) | 2007-03-02 | 2008-09-12 | Yale University | Methods for ex vivo administration of drugs to grafts using polymeric nanoparticles |
US20090155371A1 (en) | 2007-12-17 | 2009-06-18 | Sojka Milan F | Compositions Comprising Solid Particles Entrapped In Collapsed Polymeric Microspheres, And Methods Of Making The Same |
EP2252269A1 (en) * | 2008-02-11 | 2010-11-24 | Technion Research and Development Foundation, Ltd. | Casein particles encapsulating therapeutically active agents and uses thereof |
US9241898B2 (en) | 2008-03-11 | 2016-01-26 | Yale University | Compositions and methods for controlled delivery of inhibitory ribonucleic acids |
US20090312402A1 (en) | 2008-05-20 | 2009-12-17 | Contag Christopher H | Encapsulated nanoparticles for drug delivery |
US8309356B2 (en) | 2009-04-01 | 2012-11-13 | Yale University | Pseudocomplementary oligonucleotides for targeted gene therapy |
WO2010123983A1 (en) | 2009-04-21 | 2010-10-28 | Yale University | Compostions and methods for targeted gene therapy |
WO2011053989A2 (en) | 2009-11-02 | 2011-05-05 | Yale University | Polymeric materials loaded with mutagenic and recombinagenic nucleic acids |
CN106834320B (en) | 2009-12-10 | 2021-05-25 | 明尼苏达大学董事会 | TAL effector-mediated DNA modification |
US20110293585A1 (en) | 2010-04-21 | 2011-12-01 | Helix Therapeutics, Inc. | Compositions and methods for treatment of lysosomal storage disorders |
WO2011133803A1 (en) | 2010-04-21 | 2011-10-27 | Helix Therapeutics, Inc. | Compositions and methods for targeted inactivation of hiv cell surface receptors |
GB201021499D0 (en) | 2010-12-20 | 2011-02-02 | Loxbridge Res Llp | Detection of quantative genetic differnces |
WO2012151539A2 (en) | 2011-05-05 | 2012-11-08 | New York University | Lanthanoid complex capsule and particle contrast agents, methods of making and using thereof |
US9895451B2 (en) | 2011-12-02 | 2018-02-20 | Yale University | Formulations for targeted release of agents to low pH tissue environments or cellular compartments and methods of use thereof |
US9272043B2 (en) | 2011-12-02 | 2016-03-01 | Yale University | Enzymatic synthesis of poly(amine-co-esters) and methods of use thereof for gene delivery |
WO2013082529A1 (en) | 2011-12-02 | 2013-06-06 | Yale University | Enzymatic synthesis of poly(amine-co-esters) and methods of use thereof for gene delivery |
UA118014C2 (en) | 2012-05-25 | 2018-11-12 | Те Ріджентс Оф Те Юніверсіті Оф Каліфорнія | METHOD OF METHOD MODIFICATION |
CN105188767A (en) | 2012-07-25 | 2015-12-23 | 布罗德研究所有限公司 | Inducible DNA binding proteins and genome perturbation tools and applications thereof |
AU2014205662B2 (en) | 2013-01-08 | 2019-09-05 | Fred Hutchinson Cancer Research Center | Compositions and methods for expansion of embryonic hematopoietic stem cells |
EP2754684A1 (en) | 2013-01-13 | 2014-07-16 | Greenseal Chemicals NV | Method for the production of hyperbranched polyglycerol |
JP5893598B2 (en) | 2013-10-17 | 2016-03-23 | 日清食品ホールディングス株式会社 | Thermoplastic resin sheet and molded body |
CN106455542A (en) | 2014-03-26 | 2017-02-22 | 布里格姆及妇女医院股份有限公司 | Compositions and methods for ex vivo expansion of human hematopoietic stem/progenitor cells |
US20160030349A1 (en) | 2014-08-01 | 2016-02-04 | Boehringer Ingelheim Vetmedica Gmbh | Nanoparticles, methods of preparation, and uses thereof |
WO2016183217A1 (en) | 2015-05-11 | 2016-11-17 | Yale University | Functionalized polymeric particles for treatment of gliomas |
-
2015
- 2015-05-11 EP EP20166770.6A patent/EP3721875B1/en active Active
- 2015-05-11 EP EP15789794.3A patent/EP3139909A4/en active Pending
- 2015-05-11 PL PL15789223.3T patent/PL3140269T3/en unknown
- 2015-05-11 EP EP23201185.8A patent/EP4331618A3/en active Pending
- 2015-05-11 ES ES15789223T patent/ES2966886T3/en active Active
- 2015-05-11 PL PL20166770.6T patent/PL3721875T3/en unknown
- 2015-05-11 WO PCT/US2015/030169 patent/WO2015172149A1/en active Application Filing
- 2015-05-11 EP EP15789223.3A patent/EP3140269B1/en active Active
- 2015-05-11 WO PCT/US2015/030187 patent/WO2015172153A1/en active Application Filing
- 2015-05-11 US US15/309,733 patent/US10272019B2/en active Active
- 2015-05-11 US US15/309,741 patent/US10238581B2/en active Active
- 2015-05-11 ES ES20166770T patent/ES2964536T3/en active Active
-
2016
- 2016-09-19 US US15/269,456 patent/US10660828B2/en active Active
-
2019
- 2019-03-25 US US16/363,823 patent/US11364182B2/en active Active
- 2019-04-09 US US16/379,224 patent/US10758459B2/en active Active
-
2020
- 2020-05-22 US US16/882,000 patent/US11826438B2/en active Active
-
2022
- 2022-06-16 US US17/842,376 patent/US11896686B2/en active Active
-
2023
- 2023-11-20 US US18/514,738 patent/US20240173216A1/en active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060105026A1 (en) | 2003-04-04 | 2006-05-18 | Fortune David H | Tissue-adhesive formulations |
US20110060036A1 (en) | 2008-03-29 | 2011-03-10 | Emory University | Branched Multifunctional Nanoparticle Conjugates And Their Use |
US8206747B2 (en) | 2008-06-16 | 2012-06-26 | Bind Biosciences, Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
US8715736B2 (en) | 2009-04-30 | 2014-05-06 | Florida Agricultural And Mechanical University | Nanoparticle formulations for skin delivery |
US9492382B2 (en) | 2009-12-18 | 2016-11-15 | Basf Se | Hyperbranched polyester having a hydrophobic core for solubilizing active ingredients of low solubility |
US20110200666A1 (en) | 2010-02-12 | 2011-08-18 | Rovi Cosmetics International Gmbh | UV PROTECTION AGENT FOR THE SKIN OR HAIR HAVING A UV FILTER SUBSTANCE ENCAPSULATED IN A VESICULAR CARRIER SYSTEMü |
WO2012156094A1 (en) | 2011-05-18 | 2012-11-22 | Freie Universität Berlin | Nanoparticles functionalized with dendritic polyglycerol sulfate |
WO2013166487A1 (en) | 2012-05-04 | 2013-11-07 | Yale University | Highly penetrative nanocarriers for treatment of cns disease |
WO2015172149A1 (en) | 2014-05-09 | 2015-11-12 | Yale University | Hyperbranched polyglycerol-coated particles and methods of making and using thereof |
Non-Patent Citations (26)
Also Published As
Publication number | Publication date |
---|---|
WO2015172153A1 (en) | 2015-11-12 |
EP4331618A3 (en) | 2024-06-12 |
US11896686B2 (en) | 2024-02-13 |
US20240173216A1 (en) | 2024-05-30 |
EP3721875C0 (en) | 2023-11-08 |
EP3140269A4 (en) | 2018-01-03 |
EP3721875B1 (en) | 2023-11-08 |
WO2015172149A1 (en) | 2015-11-12 |
US20200000687A1 (en) | 2020-01-02 |
EP3139909A1 (en) | 2017-03-15 |
US20220323313A1 (en) | 2022-10-13 |
EP3140269C0 (en) | 2023-11-29 |
US20190380921A1 (en) | 2019-12-19 |
PL3721875T3 (en) | 2024-03-04 |
EP3721875A1 (en) | 2020-10-14 |
EP3140269B1 (en) | 2023-11-29 |
US11826438B2 (en) | 2023-11-28 |
US11364182B2 (en) | 2022-06-21 |
EP3139909A4 (en) | 2018-01-03 |
ES2964536T3 (en) | 2024-04-08 |
US20170000737A1 (en) | 2017-01-05 |
US20180177688A1 (en) | 2018-06-28 |
ES2966886T3 (en) | 2024-04-24 |
US10238581B2 (en) | 2019-03-26 |
US20170266119A1 (en) | 2017-09-21 |
EP3140269A1 (en) | 2017-03-15 |
US20210030634A1 (en) | 2021-02-04 |
US10272019B2 (en) | 2019-04-30 |
US10660828B2 (en) | 2020-05-26 |
PL3140269T3 (en) | 2024-03-11 |
EP4331618A2 (en) | 2024-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10758459B2 (en) | Topical formulation of hyperbranched polyglycerol-coated particles thereof | |
EP3294275B1 (en) | Topical formulation of hyperbranched polymer-coated particles | |
US11918695B2 (en) | Topical formulation of hyperbranched polymer-coated particles | |
Chen et al. | Multistimuli-responsive PEGylated polymeric bioconjugate-based nano-aggregate for cancer therapy | |
Mir et al. | Recent applications of PLGA based nanostructures in drug delivery | |
Nguyen et al. | Highly retina-permeating and long-acting resveratrol/metformin nanotherapeutics for enhanced treatment of macular degeneration | |
Wu et al. | Injectable and pH-responsive silk nanofiber hydrogels for sustained anticancer drug delivery | |
Zhang et al. | DNA-hybrid-gated photothermal mesoporous silica nanoparticles for NIR-responsive and aptamer-targeted drug delivery | |
Romero et al. | Surface Engineered Poly (lactide-co-glycolide) Nanoparticles for Intracellular Delivery: Uptake and Cytotoxicity A Confocal Raman Microscopic Study | |
Chen et al. | Transdermal vascular endothelial growth factor delivery with surface engineered gold nanoparticles | |
US11975109B2 (en) | Methods for targeted delivery of agents to degraded elastic fibers | |
Qiao et al. | Self-assembled ROS-sensitive polymer–peptide therapeutics incorporating built-in reporters for evaluation of treatment efficacy | |
Zhang et al. | pH-sensitive prodrug conjugated polydopamine for NIR-triggered synergistic chemo-photothermal therapy | |
US20140086975A1 (en) | Hydrogel formulation for dermal and ocular delivery | |
Kumar et al. | Impact of structural differences in hyperbranched polyglycerol–polyethylene glycol nanoparticles on dermal drug delivery and biocompatibility | |
Pramanik et al. | Stimuli-responsive nanocapsules for the spatiotemporal release of melatonin: protection against gastric inflammation | |
Calik et al. | Dendron–polymer conjugate based cross-linked micelles: a robust and versatile nanosystem for targeted delivery | |
Akhtar et al. | Impact of PAMAM delivery systems on signal transduction pathways in vivo: Modulation of ERK1/2 and p38 MAP kinase signaling in the normal and diabetic kidney | |
Sunoqrot et al. | Tuning the surface chemistry of melanin-mimetic polydopamine nanoparticles drastically enhances their accumulation into excised human skin | |
Shen et al. | A comprehensive review of advanced drug delivery systems for the treatment of rheumatoid arthritis | |
Sepulveda et al. | Biomedical applications of stimuli-responsive hydrogels | |
Mishra et al. | Topical Application of Peptide–Chondroitin Sulfate Nanoparticles Allows Efficient Photoprotection in Skin | |
Panonnummal et al. | Application of chitosan and its derivatives in transdermal drug delivery | |
Zhang et al. | Multifunctional Dendritic Au@ SPP@ DOX Nanoparticles Integrating Chemotherapy and Low-Dose Radiotherapy for Enhanced Anticancer Activity | |
Mahdieh et al. | Design of novel polyurethane-based ionene nanocarriers for cancer therapy: synthesis, in-vitro, and in-vivo studies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
AS | Assignment |
Owner name: YALE UNIVERSITY, CONNECTICUT Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DENG, YANG;EDIRIWICKREMA, ASIRI;SALTZMAN, WILLIAM M.;SIGNING DATES FROM 20150515 TO 20150516;REEL/FRAME:049472/0337 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 4 |